胃癌相关抗原MG7-Ag的鉴定和功能分析
|
摘要
胃癌是最常见的恶性肿瘤之一,其死亡率居肿瘤的第二位。对胃癌的早期诊断和治疗是胃癌研究的重大课题。胃癌早期无明显症状,发现时已到晚期,预后极差。以往的胃癌标志物如CEA、CA50等对胃癌的敏感性和特异性较低,早期诊断受到限制。因此,寻找新的组织学、细胞学、血清学的胃癌新抗原,对胃癌诊治的意义重大。
本实验室樊代明教授在上世纪八十年代研制出一系列胃癌单克隆抗体,命名为MG系列。其中,MG7-Ag对胃癌的敏感性特异性都很高。后续本实验室及国内医学专家对此进行了一系列相关深入的研究,包括胃癌单克隆抗体MG7对胃癌的诊断、评价预后及动态监测作用、MG7靶向治疗作用、特异性纳米疫苗的制备等等,在国内外发表了几十篇很有影响力的文章。
但是,MG7-Ag尚未可知,MG7单抗在国际上的推广及进一步研究受到限制。香港科技大学学者鉴定MG7-Ag为hnRNPA2?B1,但是其性质与我们的以往研究的MG7-Ag不符。本研究使用免疫沉淀、双向电泳、质谱分析等技术鉴定MG7-Ag,对于发现新的癌抗原或癌蛋白,对于胃癌新的分子机制的研究有着不可估量的重要意义。
此外,本研究拟建立一个简便的胃癌血清学早期诊断方法,用于胃癌高危人群的普查。MG7单抗对胃癌细胞凋亡作用的研究,为今后的临床药物治疗提供新的思路。
总之,本项研究有深刻的理论意义和临床应用前景。
【目的】
1、免疫组织化学检测MG7-Ag在胃粘膜组织中的表达与分布特点及与临床特征的联系;2、研究MG7-Ag与hnRNPA2/B1的表达区别;3、MG7-Ag的鉴定;4、建立检测MG7-Ag的简便的胃癌血清学早期诊断方法;5、MG7单抗对胃癌细胞凋亡及细胞周期的影响。
【方法】
1、通过细胞培养技术复苏MG7杂交瘤细胞,制备MG7单抗;2、应用免疫组化技术检测MG7-Ag在胃粘膜组织中的表达与分布特点及与临床特征的联系;3、应用免疫组化技术观察MG7-Ag与hnRNPA2/B1在胃癌组织中的表达区别;4、应用免疫细胞化学技术和扫描共聚焦显微镜观察MG7-Ag与hnRNPA2/B1在胃癌细胞中的表达区别;5、通过Western blot技术检测MG7-Ag与hnRNPA2/B1胃癌细胞中的表达区别;6、应用免疫沉淀,Western blot,双向电泳,质谱技术鉴定MG7-Ag;7、通过酶联免疫吸附方法建立检测MG7-Ag的胃癌血清学早期诊断方法;8、通过MG7-Ag的胃癌血清学早期诊断方法检测胃癌,胃癌前病变和其它各种肿瘤病人;9、流式细胞仪检测MG7抗体对胃癌细胞凋亡和细胞周期的影响。
【结果】
1、MG7-Ag在胃粘膜组织中的表达与分布及与临床特征的联系检测了MG7-Ag在胃粘膜组织(胃癌116例;浅表性胃炎,肠化,增生、萎缩性胃炎等84例)石蜡组织标本中的表达与分布情况,发现MG7-Ag阳性表达率是随着浅表性胃炎,肠化,增生,胃癌,逐渐增高的。MG7-Ag阳性分布:1.腺上皮细胞的胞浆上极和胞膜;2.胃腺腔内。胃癌旁切片染色提示:胃黏膜腺体底部上皮细胞MG7-Ag几乎全部阳性,向顶端方向阳性细胞渐减少,而顶端腔面上皮细胞MG7-Ag又多为阳性。在胃癌患者中,MG7-Ag表达与年龄、性别无关,与分化和临床分期有关。
2、MG7-Ag与hnRNPA2/B1在胃癌细胞中表达存在明显区别
我们应用免疫组化技术检测同一胃癌石蜡切块中MG7-Ag与hnRNPA2/B1在胃癌细胞中的表达,发现MG7-Ag主要分布在细胞膜,细胞核中未见阳性表达,而hnRNPA2/B1主要分布在细胞核中。应用免疫细胞化学技术和扫描共聚焦观察MG7-Ag与hnRNPA2/B1在胃癌细胞SGC7901,MKN45中的表达区别,发现MG7-Ag主要分布在细胞膜上,细胞核中未见阳性表达,而hnRNPA2/B1主要分布在细胞核中。通过Western blot技术检测MG7-Ag与hnRNPA2/B1在胃癌细胞MKN45中的区别,MG7-Ag表现为2条带,分子量分别约100KD、120KD;hnRNPA2/B1表现为2条带,分子量分别约34KD、37KD。
3、MG7-Ag的鉴定
我们通过免疫沉淀方法,将MG7抗体分别与胃癌细胞系SGC7901,MKN45,胃癌组织交联,行单向或双向电泳。与Western blot相匹配的蛋白点从银染或考马斯亮蓝染色的胶中切下,转到离心管中做质谱检测。免疫沉淀的单向电泳,银染的表观分子量为100KD的胃癌组织条带和胃癌细胞系MKN45条带,LC-MS/MS分析鉴定最可能为anti-colorectal carcinoma heavy chain;考马斯亮蓝染色的表观分子量为100KD的胃癌细胞系MKN45条带和SGC7901条带,ESI-MS/MS分析鉴定最可能为anti-human CD19 monoclonal antibody 4G7 immunoglobulin gamma1 heavy chain。
免疫沉淀的双向电泳,考马斯亮蓝染色的表观分子量为100KD的胃癌组织条带,MALDI-TOF/TOF分析鉴定为IGHG3 protein。通过Western blot技术,抗人IgG抗体可以与MG7-Ag结合,说明MG7-Ag可能为免疫球蛋白重链样分子。
4、研发检测MG7-Ag的胃癌血清学早期诊断方法及应用
应用间接酶联免疫吸附方法,生物素-亲和素放大系统,选择合适的包被条件和抗体浓度,检测胃癌手术前后,胃癌前病变和其他肿瘤患者的血清中MG7-Ag。PBS(0.01M)为阴性对照。大于阴性对照的A值的2.1倍为阳性。116例胃癌术前患者的阳性率为83.6%,明显高于胃癌术后(总63例,47.6%),胃癌前病变(总78例,12.8%)和其它肿瘤组。统计学分析差别有显著意义(P<0.01)。MG7-Ag在其他肿瘤患者血清中也有不同程度的阳性表达,如肺癌(45.2%),直肠癌(45.5%),结肠癌(17.6%),乳腺癌(14.2%),而子宫癌,淋巴瘤,急性白血病患者中未检测出。胃癌术前患者血清检测MG7-Ag的的阳性表达率随着TNM分期进展逐渐升高:Ⅰ期(总6例,33.3%),Ⅱ期(总46例,78.3%),Ⅲ期(总62例,91.9%),Ⅳ期(总2例,100%),统计学显示各组间差别有显著意义(P<0.01);N0(总30例,60.0%),≥N1(总86例,91.9%),统计学显示差别有显著意义(P<0.01)。以上结果提示,MG7-Ag是胃癌较特异性的标志,MG7-Ag的表达率随胃癌的进展而升高。间接酶联免疫吸附实验检测患者血清MG7-Ag可以作为胃癌的早期诊断的简便方法。
5、MG7单抗对胃癌细胞凋亡及细胞周期的影响。
应用流式细胞仪检测MG7单抗对胃癌细胞系KATOⅢ的凋亡影响,发现MG7单抗明显促进胃癌细胞的早期凋亡(P<0.05)。细胞周期检测,MG7单抗主要使胃癌细胞阻滞在G1期。
【结论】
本研究提示:MG7-Ag的表达水平与胃癌的分期和恶性程度相关,可能在胃癌的发生和进展中起重要的作用;MG7-Ag与hnRNPA2/B1在胃癌细胞表达中存在明显区别,MG7-Ag是hnRNPA2/B1的可能性不大;MG7-Ag可能为免疫球蛋白重链样分子;建立了MG7-Ag的胃癌血清学早期诊断方法,预计有较广阔的应用前景。MG7单抗对胃癌细胞有促进凋亡的作用,对细胞周期的影响主要在G1期。
Gastric cancer is one of the most prevalent malignancies worldwide, and is the second cause of tumor-related death. In gastric cancer researches,early diagnosis and treatment is of the most importance. Few overt symptoms are shown at the early stage of gastric cancer, while most of the diagnosis are made at the advanced stage with poor prognosis. The low sensitivity and specificity of many available cancer markers, including carcinoembryonic antigen (CEA), CA 50,etc. have hampered their use in detecting gastric carcinoma. Therefore, it is vital to seek new gastric cancer antigen at the histological, cytological and serological levels for diagnosis and treatment of gastric cancer.
A series of gastrointestinal cancer specific mAb named MG series were discovered in our lab by Prof. Fan Danming in 1980s. Among these specific antibodies, MG7 showed the highest specificity and sensitivity. Further studies of MG7, including the effects of MG7 in diagnosis, evaluation of prognosis, dynamic follow-up study and targeting therapy of gastric cancer, as well as preparation of gastric cancer specific nanovaccine, et al., have been carried out by medical experts in and out of our lab, with dozens of papers subscribed in both domestic and foreign journals.
However, up to now, little is known about MG7-Ag, which has limited the international generalization of MG7-Ab and hindered further researches. The scientists in the Hong Kong Polytechnic University have identified MG7-Ag as hnRNPA2/B1, the characteritics of which are different from that of MG7-Ag in our prevous resrarch.In the present study we used immunoprecipitation, 2-D PAGE, mass spectrometry and other methodes to identify MG7-Ag. The discovery of new gastric cancer antigens or proteins may greatly facilitate the studies of molecular mechanisms of gastric cancer.
Besides, attempts were also made in our study to establish a convenient serologic method for gastric cancer screening in the high risk population. The studies of MG7 mAb effect on gastric cancer cell apoptosis may help to find new methods in clinical pharmacal therapies.
In conclusion, our study has deepgoing theoretical values and good clinical prospects.
【Objectives】
(1) To investigate the expression or distribution of MG7-Ag in different gastric mucosal tissues and the relationship between expression intensity of MG7-Ag with the clinicopathologic characteristics of gastric cancer; (2) To examine the expression difference between MG7-Ag and hnRNPA2/B1 protein; (3) To identify MG7-Ag; (4) To establish a convenient serologic method for early diagnosis of gastric cancer by detecting MG7-Ag;(5) To investigate the effects of MG7 monoclonal antibody on apoptosis and cell cycle in human gastric cancer cell line.
【Methods】
(1) MG7 hybridoma cells were resuscitated and cultured for MG7-Ab preparation. (2)The expression or distribution characteristics of MG7-Ag in different gastric mucosal tissues were determined by immunohistochemistry assay, and the relationship between MG7-Ag expression intensity with the clinicopathologic characteristics were eveluated. (3)The expression difference between MG7-Ag and hnRNPA2/B1 protein in gastric cancer tissue was investigated by immunohistochemistry assay. (4)The expression difference between MG7-Ag and hnRNPA2/B1 protein in gastric cancer cells was detected by immunocytochemistry assay and laser scanning confocal microscope. (5)The expression difference between MG7-Ag and hnRNPA2/B1 protein in gastric cancer cells was detected by Western blot. (6) MG7-Ag identification was carried out by Immunoprecipitation, Western blot,2-D PAGE and mass spectrometry.(7) Enzyme-linked immunoadsorption assay was used to establish a convenient serologic method for early diagnosis of gastric cancer by detecting MG7-Ag. (8) The convenient serologic method for early diagnosis of gastric cancer by detecting MG7-Ag was applied in detection of gastric cancer, precancerous lesion and other tumors. (9) The effects of MG7 monoclonal antibody on apoptosis and cell cycle in human gastric cancer cell line were evaluated by flow cytometry.
【Results】
1. The expression or distribution characteristics of MG7-Ag in different gastric mucosal tissues and the relationship between MG7-Ag expression intensity with the clinicopathologic characteristics of gastric cancer.
We detected the expression and distribution of MG7-Ag by immunohistochemistry analysis in different gastric mucosal tissues(gastric cancer specimens,116; superficial gastritis,intestinal metaplasia, atypical hyperplasia and atrophic gastritis specimens, 84) and we found that the positive expression rates of MG7-Ag gradually increased in superficial gastritis, intestinal metaplasia,atypical hyperplasia and gastric cancer (P<0. 01). It indicated that the expression of MG7-Ag in gastric cancer mainly located in the upper part of kytoplasm or cell membrane in glandular epithelium cells and gastric gland intracavity. The MG7-Ag staining was positive in most of the basal epithelial cells of gastric mucosa gland, and the positive rate decreased gradually towards the top, but the MG7-Ag expression on the top cavosurface epithelial cells was mostly positive. The MG7-Ag expression was closely related with tissue differentiation and clinical phases, but not with age or sex.
2. Significant difference exists between the expression of MG7-Ag and hnRNPA2/B1 protein in gastric cancer cells
Immunohistochemistry was carried out to determine the expression of MG7-Ag and hnRNPA2/B1 on the same paraffin-embedded gastric cancer section, and the results showed that MG7-Ag expressed mainly on the cell membrane, and little in the nucleus.In contrast, the expression of hnRNPA2/B1 mainly distributed in the cell nucleus. Immunocytochemistry and laser scanning confocal microscope were carried out to detect the expression of MG7-Ag and hnRNPA2/B1 in gastric cancer cell lines SGC7901 with MKN45.The results showed that the former mainly distributed on the cell membrane and little in the nucleus, while the latter mainly distributed in the cell nucleus. Western blot carried out on gastric cancer cell line MKN45 showed that two strips with Mr of 100 kDa and 120 kDa were detected by MG7 antibody, compared with another two strips with Mr of 34 kDa and 37 kDa detected by hnRNPA2/B1 antibody.
3. The identification of MG7-Ag
MG7-Ab was crosslinked to gastric cancer cell line SGC7901, MKN45, and gastric cancer tissue respectively by immunoprecipitation technique, and 1-D or 2-D polyacrylamide gel electrophoresis was proceeded. Protein spots, which were recognized and matched to those detected on the Western blot, were excised from a sliver stained gel or a coomassie blue stained gel and transferred to microcentrifuge tubes for mass spectrometry analysis.
The two strips with Mr of 100 kDa were excised from a sliver stained gel by 1-D polyacrylamide gel electrophoresis, which were immunoprecipitate of gastric cancer tissue and MG7-Ab, immunoprecipitate of gastric cancer cell line MKN45 and MG7-Ab, respectively. Both of the strips were identified as anti-colorectal carcinoma heavy chain by LC-MS/MS analysis. The two strips with Mr of 100 kDa were excised from a coomassie blue stained gel by 1-D polyacrylamide gel electrophoresis, which were immunoprecipitate of gastric cancer cell line MKN45 and MG7-Ab, immunoprecipitate of gastric cancer cell line SGC7901 and MG7-Ab, respectively. The both strips were identified as anti-human CD19 monoclonal antibody 4G7 immunoglobulin gamma1 heavy chain by ESI-MS/MS analysis.
The strip with Mr of 100 kDa was excised from a coomassie blue stained gel by 2-D polyacrylamide gel electrophoresis, which was immunoprecipitate of gastric cancer tissue and MG7-Ab.The strip was identified as IGHG3 protein by MALDI-TOF/TOF analysis. MG7-Ag was detected using IgG antibody (anti-human) by Western blot, which indicated that MG7-Ag is Ig heavy chain- like molecular.
4. The development application of the serologic method in early diagnosis of gastric cancer by detecting MG7-Ag
Using proper coating condition and antibody concentration, indirect BA-ELISA (biotin-avidin ELISA) was carried out before and after the operation in patients with gastric cancer and patients with precancerous lesions or other tumor groups to detect MG7-Ag in sera. PBS (0.01M) was taken as the negative control. A sample was considered“positive”if its absorbance was 2.1-fold of or higher than the negative value. The positive rate of gastric cancer-related MG7-Ag determined by ELISA was 83.6% in preoperative gastric cancer patients (97 of 116),which is higher than that of postoperative patients(63, 47.6%), precancerous lesions patients(78,12.8%), and other tumor groups, respectively (P <0.01). MG7-Ag can also be detected in sera of patients with other tumors (45.2% for lung cancer, 45.5% for rectal cancer, 17.6% for colonic cancer, and 14.2% for breast cancer), but no MG7-Ag was detected in sera of patients with endometrial cancer, lymphoma, or acute leukemia. The expression level of circulating MG7-Ag was significantly associated with TNM stage (P < 0.01) and lymph node metastasis (N0, 30, 73.3%;≥N1, 86,95.3%,P < 0.01). The positive rate of circulating MG7-Ag in stageⅠ(6, 50%),Ⅱ(46, 84.8%),Ⅲ(62, 96.8%) andⅣ(2, 100%)increased gradually. The above results indicated that MG7-Ag was a relatively specific marker in gastric cancer, and the expression of MG7-Ag was positive gradually along with the advancement of gastric cancer. The indirect BA-ELISA (biotin-avidin ELISA) method carried out to detect MG7-Ag in sera of patients may be taken as a convenient method for early diagnosis of gastric cancer.
5. The effect of MG7 monoclonal antibody on apoptosis and cell cycle in human gastric cancer cell line
Flow cytometry was applied to detect the effect of MG7 monoclonal antibody on apoptosis and cell cycle in human gastric cancer cell line KATOⅢ.The results showed that MG7 monoclonal antibody would enhance the early apoptosis in human gastric cancer cell(P<0.05) and induce cell cycle arrest at G1 phrase remarkably.
【Conclusions】
In conclusion, the expression of MG7-Ag was statistically correlated with the differentiation level (P <0.01) and pathological stage (P <0.01) of gastric cancer. It indicated that MG7-Ag may play an important role in gastric cancer carcinogenesis. There was significant difference between the expression of MG7-Ag and hnRNPA2/B1 protein in gastric cancer cells. It indicated that MG7-Ag and hnRNPA2/B1 were not the same. MG7-Ag may be Ig heavy chain- like molecular. A serologic method for early diagnosis of gastric cancer was established by enzyme-linked immunoadsordent assay, with promising values in clinical use. MG7 monoclonal antibody would enhance the early apoptosis in human gastric cancer cells (P<0.05) and may induce cell cycle arrest at G1 phrase remarkably.
本实验室樊代明教授在上世纪八十年代研制出一系列胃癌单克隆抗体,命名为MG系列。其中,MG7-Ag对胃癌的敏感性特异性都很高。后续本实验室及国内医学专家对此进行了一系列相关深入的研究,包括胃癌单克隆抗体MG7对胃癌的诊断、评价预后及动态监测作用、MG7靶向治疗作用、特异性纳米疫苗的制备等等,在国内外发表了几十篇很有影响力的文章。
但是,MG7-Ag尚未可知,MG7单抗在国际上的推广及进一步研究受到限制。香港科技大学学者鉴定MG7-Ag为hnRNPA2?B1,但是其性质与我们的以往研究的MG7-Ag不符。本研究使用免疫沉淀、双向电泳、质谱分析等技术鉴定MG7-Ag,对于发现新的癌抗原或癌蛋白,对于胃癌新的分子机制的研究有着不可估量的重要意义。
此外,本研究拟建立一个简便的胃癌血清学早期诊断方法,用于胃癌高危人群的普查。MG7单抗对胃癌细胞凋亡作用的研究,为今后的临床药物治疗提供新的思路。
总之,本项研究有深刻的理论意义和临床应用前景。
【目的】
1、免疫组织化学检测MG7-Ag在胃粘膜组织中的表达与分布特点及与临床特征的联系;2、研究MG7-Ag与hnRNPA2/B1的表达区别;3、MG7-Ag的鉴定;4、建立检测MG7-Ag的简便的胃癌血清学早期诊断方法;5、MG7单抗对胃癌细胞凋亡及细胞周期的影响。
【方法】
1、通过细胞培养技术复苏MG7杂交瘤细胞,制备MG7单抗;2、应用免疫组化技术检测MG7-Ag在胃粘膜组织中的表达与分布特点及与临床特征的联系;3、应用免疫组化技术观察MG7-Ag与hnRNPA2/B1在胃癌组织中的表达区别;4、应用免疫细胞化学技术和扫描共聚焦显微镜观察MG7-Ag与hnRNPA2/B1在胃癌细胞中的表达区别;5、通过Western blot技术检测MG7-Ag与hnRNPA2/B1胃癌细胞中的表达区别;6、应用免疫沉淀,Western blot,双向电泳,质谱技术鉴定MG7-Ag;7、通过酶联免疫吸附方法建立检测MG7-Ag的胃癌血清学早期诊断方法;8、通过MG7-Ag的胃癌血清学早期诊断方法检测胃癌,胃癌前病变和其它各种肿瘤病人;9、流式细胞仪检测MG7抗体对胃癌细胞凋亡和细胞周期的影响。
【结果】
1、MG7-Ag在胃粘膜组织中的表达与分布及与临床特征的联系检测了MG7-Ag在胃粘膜组织(胃癌116例;浅表性胃炎,肠化,增生、萎缩性胃炎等84例)石蜡组织标本中的表达与分布情况,发现MG7-Ag阳性表达率是随着浅表性胃炎,肠化,增生,胃癌,逐渐增高的。MG7-Ag阳性分布:1.腺上皮细胞的胞浆上极和胞膜;2.胃腺腔内。胃癌旁切片染色提示:胃黏膜腺体底部上皮细胞MG7-Ag几乎全部阳性,向顶端方向阳性细胞渐减少,而顶端腔面上皮细胞MG7-Ag又多为阳性。在胃癌患者中,MG7-Ag表达与年龄、性别无关,与分化和临床分期有关。
2、MG7-Ag与hnRNPA2/B1在胃癌细胞中表达存在明显区别
我们应用免疫组化技术检测同一胃癌石蜡切块中MG7-Ag与hnRNPA2/B1在胃癌细胞中的表达,发现MG7-Ag主要分布在细胞膜,细胞核中未见阳性表达,而hnRNPA2/B1主要分布在细胞核中。应用免疫细胞化学技术和扫描共聚焦观察MG7-Ag与hnRNPA2/B1在胃癌细胞SGC7901,MKN45中的表达区别,发现MG7-Ag主要分布在细胞膜上,细胞核中未见阳性表达,而hnRNPA2/B1主要分布在细胞核中。通过Western blot技术检测MG7-Ag与hnRNPA2/B1在胃癌细胞MKN45中的区别,MG7-Ag表现为2条带,分子量分别约100KD、120KD;hnRNPA2/B1表现为2条带,分子量分别约34KD、37KD。
3、MG7-Ag的鉴定
我们通过免疫沉淀方法,将MG7抗体分别与胃癌细胞系SGC7901,MKN45,胃癌组织交联,行单向或双向电泳。与Western blot相匹配的蛋白点从银染或考马斯亮蓝染色的胶中切下,转到离心管中做质谱检测。免疫沉淀的单向电泳,银染的表观分子量为100KD的胃癌组织条带和胃癌细胞系MKN45条带,LC-MS/MS分析鉴定最可能为anti-colorectal carcinoma heavy chain;考马斯亮蓝染色的表观分子量为100KD的胃癌细胞系MKN45条带和SGC7901条带,ESI-MS/MS分析鉴定最可能为anti-human CD19 monoclonal antibody 4G7 immunoglobulin gamma1 heavy chain。
免疫沉淀的双向电泳,考马斯亮蓝染色的表观分子量为100KD的胃癌组织条带,MALDI-TOF/TOF分析鉴定为IGHG3 protein。通过Western blot技术,抗人IgG抗体可以与MG7-Ag结合,说明MG7-Ag可能为免疫球蛋白重链样分子。
4、研发检测MG7-Ag的胃癌血清学早期诊断方法及应用
应用间接酶联免疫吸附方法,生物素-亲和素放大系统,选择合适的包被条件和抗体浓度,检测胃癌手术前后,胃癌前病变和其他肿瘤患者的血清中MG7-Ag。PBS(0.01M)为阴性对照。大于阴性对照的A值的2.1倍为阳性。116例胃癌术前患者的阳性率为83.6%,明显高于胃癌术后(总63例,47.6%),胃癌前病变(总78例,12.8%)和其它肿瘤组。统计学分析差别有显著意义(P<0.01)。MG7-Ag在其他肿瘤患者血清中也有不同程度的阳性表达,如肺癌(45.2%),直肠癌(45.5%),结肠癌(17.6%),乳腺癌(14.2%),而子宫癌,淋巴瘤,急性白血病患者中未检测出。胃癌术前患者血清检测MG7-Ag的的阳性表达率随着TNM分期进展逐渐升高:Ⅰ期(总6例,33.3%),Ⅱ期(总46例,78.3%),Ⅲ期(总62例,91.9%),Ⅳ期(总2例,100%),统计学显示各组间差别有显著意义(P<0.01);N0(总30例,60.0%),≥N1(总86例,91.9%),统计学显示差别有显著意义(P<0.01)。以上结果提示,MG7-Ag是胃癌较特异性的标志,MG7-Ag的表达率随胃癌的进展而升高。间接酶联免疫吸附实验检测患者血清MG7-Ag可以作为胃癌的早期诊断的简便方法。
5、MG7单抗对胃癌细胞凋亡及细胞周期的影响。
应用流式细胞仪检测MG7单抗对胃癌细胞系KATOⅢ的凋亡影响,发现MG7单抗明显促进胃癌细胞的早期凋亡(P<0.05)。细胞周期检测,MG7单抗主要使胃癌细胞阻滞在G1期。
【结论】
本研究提示:MG7-Ag的表达水平与胃癌的分期和恶性程度相关,可能在胃癌的发生和进展中起重要的作用;MG7-Ag与hnRNPA2/B1在胃癌细胞表达中存在明显区别,MG7-Ag是hnRNPA2/B1的可能性不大;MG7-Ag可能为免疫球蛋白重链样分子;建立了MG7-Ag的胃癌血清学早期诊断方法,预计有较广阔的应用前景。MG7单抗对胃癌细胞有促进凋亡的作用,对细胞周期的影响主要在G1期。
Gastric cancer is one of the most prevalent malignancies worldwide, and is the second cause of tumor-related death. In gastric cancer researches,early diagnosis and treatment is of the most importance. Few overt symptoms are shown at the early stage of gastric cancer, while most of the diagnosis are made at the advanced stage with poor prognosis. The low sensitivity and specificity of many available cancer markers, including carcinoembryonic antigen (CEA), CA 50,etc. have hampered their use in detecting gastric carcinoma. Therefore, it is vital to seek new gastric cancer antigen at the histological, cytological and serological levels for diagnosis and treatment of gastric cancer.
A series of gastrointestinal cancer specific mAb named MG series were discovered in our lab by Prof. Fan Danming in 1980s. Among these specific antibodies, MG7 showed the highest specificity and sensitivity. Further studies of MG7, including the effects of MG7 in diagnosis, evaluation of prognosis, dynamic follow-up study and targeting therapy of gastric cancer, as well as preparation of gastric cancer specific nanovaccine, et al., have been carried out by medical experts in and out of our lab, with dozens of papers subscribed in both domestic and foreign journals.
However, up to now, little is known about MG7-Ag, which has limited the international generalization of MG7-Ab and hindered further researches. The scientists in the Hong Kong Polytechnic University have identified MG7-Ag as hnRNPA2/B1, the characteritics of which are different from that of MG7-Ag in our prevous resrarch.In the present study we used immunoprecipitation, 2-D PAGE, mass spectrometry and other methodes to identify MG7-Ag. The discovery of new gastric cancer antigens or proteins may greatly facilitate the studies of molecular mechanisms of gastric cancer.
Besides, attempts were also made in our study to establish a convenient serologic method for gastric cancer screening in the high risk population. The studies of MG7 mAb effect on gastric cancer cell apoptosis may help to find new methods in clinical pharmacal therapies.
In conclusion, our study has deepgoing theoretical values and good clinical prospects.
【Objectives】
(1) To investigate the expression or distribution of MG7-Ag in different gastric mucosal tissues and the relationship between expression intensity of MG7-Ag with the clinicopathologic characteristics of gastric cancer; (2) To examine the expression difference between MG7-Ag and hnRNPA2/B1 protein; (3) To identify MG7-Ag; (4) To establish a convenient serologic method for early diagnosis of gastric cancer by detecting MG7-Ag;(5) To investigate the effects of MG7 monoclonal antibody on apoptosis and cell cycle in human gastric cancer cell line.
【Methods】
(1) MG7 hybridoma cells were resuscitated and cultured for MG7-Ab preparation. (2)The expression or distribution characteristics of MG7-Ag in different gastric mucosal tissues were determined by immunohistochemistry assay, and the relationship between MG7-Ag expression intensity with the clinicopathologic characteristics were eveluated. (3)The expression difference between MG7-Ag and hnRNPA2/B1 protein in gastric cancer tissue was investigated by immunohistochemistry assay. (4)The expression difference between MG7-Ag and hnRNPA2/B1 protein in gastric cancer cells was detected by immunocytochemistry assay and laser scanning confocal microscope. (5)The expression difference between MG7-Ag and hnRNPA2/B1 protein in gastric cancer cells was detected by Western blot. (6) MG7-Ag identification was carried out by Immunoprecipitation, Western blot,2-D PAGE and mass spectrometry.(7) Enzyme-linked immunoadsorption assay was used to establish a convenient serologic method for early diagnosis of gastric cancer by detecting MG7-Ag. (8) The convenient serologic method for early diagnosis of gastric cancer by detecting MG7-Ag was applied in detection of gastric cancer, precancerous lesion and other tumors. (9) The effects of MG7 monoclonal antibody on apoptosis and cell cycle in human gastric cancer cell line were evaluated by flow cytometry.
【Results】
1. The expression or distribution characteristics of MG7-Ag in different gastric mucosal tissues and the relationship between MG7-Ag expression intensity with the clinicopathologic characteristics of gastric cancer.
We detected the expression and distribution of MG7-Ag by immunohistochemistry analysis in different gastric mucosal tissues(gastric cancer specimens,116; superficial gastritis,intestinal metaplasia, atypical hyperplasia and atrophic gastritis specimens, 84) and we found that the positive expression rates of MG7-Ag gradually increased in superficial gastritis, intestinal metaplasia,atypical hyperplasia and gastric cancer (P<0. 01). It indicated that the expression of MG7-Ag in gastric cancer mainly located in the upper part of kytoplasm or cell membrane in glandular epithelium cells and gastric gland intracavity. The MG7-Ag staining was positive in most of the basal epithelial cells of gastric mucosa gland, and the positive rate decreased gradually towards the top, but the MG7-Ag expression on the top cavosurface epithelial cells was mostly positive. The MG7-Ag expression was closely related with tissue differentiation and clinical phases, but not with age or sex.
2. Significant difference exists between the expression of MG7-Ag and hnRNPA2/B1 protein in gastric cancer cells
Immunohistochemistry was carried out to determine the expression of MG7-Ag and hnRNPA2/B1 on the same paraffin-embedded gastric cancer section, and the results showed that MG7-Ag expressed mainly on the cell membrane, and little in the nucleus.In contrast, the expression of hnRNPA2/B1 mainly distributed in the cell nucleus. Immunocytochemistry and laser scanning confocal microscope were carried out to detect the expression of MG7-Ag and hnRNPA2/B1 in gastric cancer cell lines SGC7901 with MKN45.The results showed that the former mainly distributed on the cell membrane and little in the nucleus, while the latter mainly distributed in the cell nucleus. Western blot carried out on gastric cancer cell line MKN45 showed that two strips with Mr of 100 kDa and 120 kDa were detected by MG7 antibody, compared with another two strips with Mr of 34 kDa and 37 kDa detected by hnRNPA2/B1 antibody.
3. The identification of MG7-Ag
MG7-Ab was crosslinked to gastric cancer cell line SGC7901, MKN45, and gastric cancer tissue respectively by immunoprecipitation technique, and 1-D or 2-D polyacrylamide gel electrophoresis was proceeded. Protein spots, which were recognized and matched to those detected on the Western blot, were excised from a sliver stained gel or a coomassie blue stained gel and transferred to microcentrifuge tubes for mass spectrometry analysis.
The two strips with Mr of 100 kDa were excised from a sliver stained gel by 1-D polyacrylamide gel electrophoresis, which were immunoprecipitate of gastric cancer tissue and MG7-Ab, immunoprecipitate of gastric cancer cell line MKN45 and MG7-Ab, respectively. Both of the strips were identified as anti-colorectal carcinoma heavy chain by LC-MS/MS analysis. The two strips with Mr of 100 kDa were excised from a coomassie blue stained gel by 1-D polyacrylamide gel electrophoresis, which were immunoprecipitate of gastric cancer cell line MKN45 and MG7-Ab, immunoprecipitate of gastric cancer cell line SGC7901 and MG7-Ab, respectively. The both strips were identified as anti-human CD19 monoclonal antibody 4G7 immunoglobulin gamma1 heavy chain by ESI-MS/MS analysis.
The strip with Mr of 100 kDa was excised from a coomassie blue stained gel by 2-D polyacrylamide gel electrophoresis, which was immunoprecipitate of gastric cancer tissue and MG7-Ab.The strip was identified as IGHG3 protein by MALDI-TOF/TOF analysis. MG7-Ag was detected using IgG antibody (anti-human) by Western blot, which indicated that MG7-Ag is Ig heavy chain- like molecular.
4. The development application of the serologic method in early diagnosis of gastric cancer by detecting MG7-Ag
Using proper coating condition and antibody concentration, indirect BA-ELISA (biotin-avidin ELISA) was carried out before and after the operation in patients with gastric cancer and patients with precancerous lesions or other tumor groups to detect MG7-Ag in sera. PBS (0.01M) was taken as the negative control. A sample was considered“positive”if its absorbance was 2.1-fold of or higher than the negative value. The positive rate of gastric cancer-related MG7-Ag determined by ELISA was 83.6% in preoperative gastric cancer patients (97 of 116),which is higher than that of postoperative patients(63, 47.6%), precancerous lesions patients(78,12.8%), and other tumor groups, respectively (P <0.01). MG7-Ag can also be detected in sera of patients with other tumors (45.2% for lung cancer, 45.5% for rectal cancer, 17.6% for colonic cancer, and 14.2% for breast cancer), but no MG7-Ag was detected in sera of patients with endometrial cancer, lymphoma, or acute leukemia. The expression level of circulating MG7-Ag was significantly associated with TNM stage (P < 0.01) and lymph node metastasis (N0, 30, 73.3%;≥N1, 86,95.3%,P < 0.01). The positive rate of circulating MG7-Ag in stageⅠ(6, 50%),Ⅱ(46, 84.8%),Ⅲ(62, 96.8%) andⅣ(2, 100%)increased gradually. The above results indicated that MG7-Ag was a relatively specific marker in gastric cancer, and the expression of MG7-Ag was positive gradually along with the advancement of gastric cancer. The indirect BA-ELISA (biotin-avidin ELISA) method carried out to detect MG7-Ag in sera of patients may be taken as a convenient method for early diagnosis of gastric cancer.
5. The effect of MG7 monoclonal antibody on apoptosis and cell cycle in human gastric cancer cell line
Flow cytometry was applied to detect the effect of MG7 monoclonal antibody on apoptosis and cell cycle in human gastric cancer cell line KATOⅢ.The results showed that MG7 monoclonal antibody would enhance the early apoptosis in human gastric cancer cell(P<0.05) and induce cell cycle arrest at G1 phrase remarkably.
【Conclusions】
In conclusion, the expression of MG7-Ag was statistically correlated with the differentiation level (P <0.01) and pathological stage (P <0.01) of gastric cancer. It indicated that MG7-Ag may play an important role in gastric cancer carcinogenesis. There was significant difference between the expression of MG7-Ag and hnRNPA2/B1 protein in gastric cancer cells. It indicated that MG7-Ag and hnRNPA2/B1 were not the same. MG7-Ag may be Ig heavy chain- like molecular. A serologic method for early diagnosis of gastric cancer was established by enzyme-linked immunoadsordent assay, with promising values in clinical use. MG7 monoclonal antibody would enhance the early apoptosis in human gastric cancer cells (P<0.05) and may induce cell cycle arrest at G1 phrase remarkably.
引文
1. 陈慰峰.医学免疫学, 北京:人民卫生出版, 2000.32.
2. Fan DM., Zhang XY., Chen XT., Mou ZX., Hu JL., Qiao TD., Chen BJ.,Wang JY., Zhang ZQ.,Gao ZQ.,Establishment of four monoclonal antibodies to a poorly differentiated gastric cancer cell line MKN-46-9 and immuno-histochemical study on their corresponding antigens. Medical Journal of Chinese People's Liberation Army. 1988; 13, 488-489.
3. Ren J., Fan DM., Zhou SJ., Zhang XY., Yang AG., Li MF., Chen Z. Establishment of immuno-PCR technique for the detection of tumor associated antigen MG7-Ag on the gastric cancer cell line. Chinese Journal of Oncology. 1994 ;16,247-250.
4. Ren. J., Chen Z., Juan SJ., Yong XY., Pan BR., Fan DM. Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique. Cancer.2000; 88, 280–285.
5. Huang LQ., Guo GH.,Cai J.,Ren J.Clinical significance of serum MG7Ag in gastric cancer and precancerous lesion.Journal of Postgraduates of Medicine (Surgery Edition) .2004; 27 ,21-22.
6. Guo DL., Ning PF., Wang L., Yuan Y. Dynamic expression of antigen MG7 in the gastric cancer and gastric precancerous lesions. Zhonghua Liu Xing Bing Xue Za Zhi. 2003 ;24(6),494-497.
7. Guo DL, Dong M, Wang L, Sun LP, Yuan Y. Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori -associated gastric diseases. World J Gastroenterol. 2002;8(6),1009-1013.
8. Zhang X., Hong L., Chan WY., Qiao T., Chen B.,Liu Y.,Fan D.Expression of MG7-Ag in patients with gastric cancer correlates with weaker T cell immune response and moreproinflammatory cytokine secretion. Biochem Cell Biol.2006 ;84,135-141.
9. 张裕民,邓敬兰,彭勇,秦云才,杨思齐.胃癌131 I-MG7 瘤内注射药代动力学及辐射剂量估算.中华核医学杂志.1998;18,61-62.
10. 邓敬兰,周润锁,张裕民,周绍娟,陈敏,林国成,彭勇,秦云才,杨思齐.131I-抗胃癌单抗在胃癌患者体内的动态分布观察. 中华核医学杂志. 1997 ;17, 114-115.
11. 秦云才,彭勇,杨思齐,邓敬兰,周雯,仇凯,周润锁,张裕民,王培杰. 131 I-MG7胃癌内注射治疗的临床研究.中华消化内镜杂志.1998;15,136-138.
12. 何凤田,聂勇战,韩者艺,陈宝军,乔太东,樊代明. 胃癌单克隆抗体MG7的噬菌体呈现型抗独特型单链抗体ScFv的制备.中华医学杂志.2001;81(1),33-36.
13. Fengtian H., Yongzhan N., Baojun C., Taidong Q., Zheyi H., Daiming F. Production of phage-displayed anti-idiotypic antibody single chain variable fragments to MG7 monoclonal antibody directed against gastric carcinoma. Chin Med Sci J. 2002 ;17,215-219.
14. 喻召才,丁杰,樊代明,张学庸. 利用噬菌体呈现技术筛选单抗MG7 ScFv 片段.细胞与分子免疫学杂志. 2001;17(6),564-565.
15. Zhaocai Y., Jie D., Borong P., Daiming F., Xueyong Z. Expression and bioactivity identification of soluble MG7 scFv . World J Gastroenterol. 2002;8,99-102.
16. 喻召才, 丁杰, 樊代明, 张学庸. MG7 胞内抗体的表达及活性鉴定.免疫学杂志.2001;17(6),410-412.
17. 徐立,乔泰东,陈宝军,欧阳为明,丁杰,张庆华,周隽,吴昕彦,金伯泉,樊代明.胃癌相关抗原MG7-Ag 模拟肽表位的筛选及测序分析. 中华医学杂志.2000 ;80(4),304-307.
18. 韩全利,丁杰,巩爱春,喻召才,乔泰东,陈宝军,张学庸,樊代明.胃癌相关抗原表位模拟短肽的筛选. 细胞与分子免疫学杂志.2003 ;19 (3),308-310.
19. 韩全利,丁杰,何凤田,喻召才,樊代明. 胃癌相关抗原模拟表位的筛选及鉴定. 中华微生物学和免疫学杂志.2001;21(2),164-165.
20. 韩全利,丁杰,喻召才, 何凤田,樊代明. 应用噬菌体肽库筛选胃癌相关抗原模拟表位. 第四军医大学学报.2000;21 (9),1162-1164.
21. Li Xu., Boquan Jin., Daiming Fan. Selection and Identification of Mimic Epitopes for Gastric Cancer-associated Antigen MG7-Ag. Molecular Cancer Therapeutics. 2003;2,301–306.
22. 孟繁平,丁杰, 喻召才,韩全利,郭长存,刘娜,樊代明.胃癌MG7-Ag 模拟表位减毒鼠伤寒沙门菌活菌疫苗研制及免疫效果. 中华消化杂志.2005;25(9),546-549.
23. 徐立, 徐宏勇,马福成,金伯泉,樊代明. 噬菌体抗原模拟表位的免疫原性研究.中华肿瘤杂志. 2001;23(3),187-189.
24. 郭长存,丁杰,喻召才,韩全利,孟繁平,樊代明. 基于胃癌MG7-Ag 模拟表位基因疫苗的构建. 第四军医大学学报.2002;23(2),107-110.
25. 郭长存,丁杰,喻召才,韩全利,孟繁平,刘娜,樊代明. 胃癌MG7-Ag 模拟表位口服DNA疫苗的研制.中华肿瘤杂志.2002 ;24(2),110-113.
26. 师瑞,吴开春,吴道澄,宁晓暄,林涛,樊代明.胃癌特异性纳米疫苗的制备及其生物学活性的研究. 中国肿瘤生物治疗杂志.2005;12(1),9-12.
27. Shi R., Hong L., Wu D., Ning X, Chen Y, Lin T, Fan D, Wu K.Enhanced Immune Response to Gastric Cancer Specific Antigen Peptide by Coencapsulation with CpG Oligodeoxynucleotides in Nanoem sion. Cancer Biology & Therapy. 2005;4(2), 218-224.
28. Chen Y, Wu K, Guo C, Liu C, Han S, Lin T, Ning X, Shi R, Shi Y, Fan D. A novel DNA vaccine containing four mimicry epitopes for gastric cancer. Cancer Biol Ther.2005; 4(3),308-312.
29. Zhang JR., Zhang XY., Chen XT., Gu TJ.,Zhang. DS.A new gastric cancer antigen associated glycolipid and glycoprotein.J Med Coll PLA.1990; 5,63-65.
30. 丁杰,王福安,张学庸.胃癌单克隆抗体MG7相应抗原与DBA受体在胃癌细胞中的电镜双标记定位.第四军医大学学报.1993;14 (3), 172-174.
31. 耿明,刘晓红,张培忠,张福洲,郝志军.胃癌超微结构与M G7-Ag分布的关系. 实用癌症杂志.1997;12(3),189-190.
32. Liu J., Lin Y., Zhang L.Detection of MG7 antigen expression in predicting high-risk in gastric cancer by automatic image analysis. Zhonghua Yu Fang Yi Xue Za Zhi. 1996 ;30(5),286-288.
33. Liu J., Hu JL., Zhang XY., Qiao TD., Chen XT., Wu KC., Ding J., Fan DM. The value of MG7 antigen in predicting cancerous change in dysplastic gastric mucosa. Int J Clin Pract. 2002 ;56(3),169-72.
34. 扎西措姆,吴开春,乔泰东,申慧琴,杜安春,索朗多杰,黄跃,樊代明.藏族和汉族胃癌相关抗原MG7-Ag表达差异的分析. 中华内科杂志.2004; 43(4), 643-646.
35. Yunping Z.,Yaoguang J., Ruwen W.,Xiushan Z.,Xin W., Bin J., Yuanyuan L.,Taidong Q.,Liu H., Daiming F.Expression and Prognostic Value of MG7-Ag in Patients With Surgically Resectable Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2007 ;14(9),2621-2627.
36. 韩英,时永全,聂永战,何风田,樊代明.MG7Ag 在胃癌细胞系SGC 7901 及其耐药亚系中的表达及功能.解放军医学杂志.2001 ;26 (6), 396-398.
37. 扎西措姆,吴开春,韩霜,潘阳林,韩者艺,申慧琴,樊代明.胃癌及非癌组织中环氧合酶-2 和人胃癌相关MG7 -Ag表达及意义.中华消化杂志.2004 ;24(11), 643- 646.
38. 赵斌燕 ,齐峰. Decorin因子对人胃癌细胞及其表达的MG7蛋白的作用.中华医学研究杂志. 2006;6(1),19-20.
39. 侯云修, 王巧银.MG7-Ag与AgNOR联用鉴别胃癌与癌前病变.西安医科大学学报.1998;19(3),428-430.
40. 金国元,孟迟,蒋敬庭,邓海峰. 血清MG7-Ag 、CA19-9 和IAP 联合检测对胃癌的诊断价值. 苏州医学院学报.2001 ;21 (1),72-73.
41. 左国庆,王景,沈鼎明.血清MG7-Ag和TAG-72 对胃癌的诊断价值.四川医学.2000 ;21 (1),25-26.
42. 刘军,左国庆.血清MG7-Ag和TAG-72在胃癌诊断中的应用.实用医学杂志.1999 ;15 (11),895-896.
43. 李新华,胡家露,陈铭声,林国成. 血清肿瘤标志物MG7Ag ,TAG72 ,CA19-9诊断胃癌的前瞻性对照研究.解放军医学杂志.1996;21(5),326-329.
44. Carpenter B., MacKay C., Alnabulsi A., MacKay M., Telfer C., Melvin WT., Murray GI.The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta. 2006 ;1765,85-100.
45. Choi YD., Dreyfuss G. Isolation of the heterogeneous nuclear RNA–ribonucleoprotein complex (hnRNP): a unique supramolecular assembly. Proc. Natl. Acad. Sci. U. S. A. 1984; 81,7471–7475.
46. Pi?ol-Roma S.,Choi YD.,Matunis MJ.,Dreyfuss G. Immunopurification of heterogeneous nuclear ribonucleoprotein particles reveals an assortment of RNA- binding proteins.Genes Dev. 1988;2, 215–227.
47. Dreyfuss G., Matunis MJ., Pi?ol-Roma S., Burd CG. HnRNP proteins and the biogenesis of mRNA, Annu. Rev. Biochem. 1993;62,289–321.
48. Saccone S., Biamonti G., Maugeri S., Bassi MT., Bunone G., Riva S., Della VG. Assignment of the human heterogeneous nuclear ribonucleoprotein A1 gene (hnRNP A1) to chromosome 12q13.1 by cDNA competitive in situ hybridization. Genomics. 1992;12,171–174.
49. Biamonti G., Buvoli M., Bassi MT., Morandi C., Cobianchi F., Riva S. Isolation of an active gene encoding human hnRNP protein A1. Evidence for alternative splicing, J. Mol. Biol.1989;207,491–503.
50. Buvoli M., Biamonti G., Tsoulfas P., Bassi MT., Ghetti A., Riva S., Morandi C. cDNAcloning of human hnRNP protein A1 reveals the existence of multiple mRNA isoforms.Nucleic Acids Res.1988;16,3751–3770.
51. Biamonti G., Ruggiu M., Saccone S., Della VG., Riva S. Two homologous genes, originated by duplication, encode the human hnRNP proteins A2 and A1. Nucleic Acids Res. 1994;22,1996–2002.
52. Burd CG., Swanson. MS., G?rlach M., Dreyfuss G..Primary structures of the heterogeneous nuclear ribonucleoprotein A2, B1, and C2 proteins: a diversity of RNA binding proteins is generated by small peptide inserts. Proc. Natl. Acad. Sci U. S. A.1989;86, 9788–9792.
53. Swanson MS., Nakagawa TY., LeVan K., Dreyfuss G. Primary structure of human nuclear ribonucleoprotein particle C proteins:conservation of sequence and domain structures in heterogeneous nuclear RNA, mRNA, and pre-rRNA-binding proteins. Mol. Cell. Biol.1987;7,1731–1739.
54. Dempsey LA., Li MJ., DePace A., Bray-Ward P., Maizels N. The human HNRPD locus maps to 4q21 and encodes a highly conserved protein.Genomics. 1998;49, 378–384.
55. Wagner BJ., DeMaria CT., Sun Y., Wilson GM.,Brewer G. Structure and genomic organization of the human AUF1 gene: alternative premRNA splicing generates four protein isoforms.Genomics.1998;48,195–202.
56. Makeyev AV., Chkheidze AN., Liebhaber SA.A set of highly conserved RNA- binding proteins, alphaCP-1 and alphaCP-2, implicated in mRNA stabilization, are coexpressed from an intronless gene and its intron-containing paralog.J. Biol. Chem.1999; 274, 24849–24857.
57. Honoré B., Rasmussen HH., Vorum H., Dejgaard K., Liu X., Gromov P., Madsen P., Gesser B., Tommerup N., Celis JE.Heterogeneous nuclear ribonucleoproteins H, H′, and F are members of a ubiquitously expressed subfamily of related but distinct proteinsencoded by genes mapping to different chromosomes.J. Biol. Chem.1995; 270, 28780– 28789.
58. Soulard M., Della VV., Siomi MC., Pi?ol-Roma S., Codogno P., Bauvy C., Bellini M., Lacroix JC., Monod G ., Dreyfuss. G . HnRNP G: sequence and characterization of a glycosylated RNA-binding protein. Nucleic Acids Res. 1993;21, 4210–4217.
59. Romanelli MG.,Lorenzi P.,Morandi C.Organization of the human gene encoding heterogeneous nuclear ribonucleoprotein type I (hnRNP I) and characterization of hnRNP I related pseudogene. Gene .2000;255,267–272.
60. Patton JG., Mayer SA., Tempst P., Nadal-Ginard B.Characterization and molecular cloning of polypyrimidine tract-binding protein: a component of a complex necessary for pre-mRNA splicing, Genes Dev.1991;5,1237–1251.
61. Ghetti A., Pi?ol-Roma S., Michael WM., Morandi C., Dreyfuss G. HnRNP I, the polypyrimidine tract-binding protein: distinct nuclear localization and association with hnRNAs. Nucleic Acids Res.1992;20, 3671–3678.
62. Mahé D., M?hl P., Gattoni R., Fischer N., Mattei MG., Stévenin J., Fuchs JP. Cloning of human 2H9 heterogeneous nuclear ribonucleoproteins. Relation with splicing and early heat shock-induced splicing arrest. J. Biol. Chem.1997; 272,1827–1836.
63. Honoré B.The hnRNP 2H9 gene, which is involved in the splicing reaction, is a multiply spliced gene.Biochim. Biophys. Acta. 2000;1492,108–119.
64. Dejgaard K., Leffers H., Rasmussen HH., Madsen P., Kruse TA., Gesser B., Nielsen H., Celis JE.Identification, molecular cloning, expression and chromosome mapping of a family of transformation upregulated hnRNP-K proteins derived by alternative splicing.J. Mol. Biol.1994;236,33–48.
65. Pi?ol-Roma S., Swanson MS., Gall JG., Dreyfuss G.A novelheterogeneous nuclear RNP protein with a unique distribution on nascent transcripts. J. Cell. Biol.1989;109,2575–2587.
66. Blanck O., Perrin C., Mziaut H., Darbon H., Mattei MG., Miquelis R. Molecular cloning, cDNA analysis, and localization of a monomer of the N-acetylglucosamine- specific receptor of the thyroid, NAGR1, to chromosome 19p13.3-13.2.Genomics. 1994;21, 18–26.
67. Gattoni R., Mahé D., M?hl P., Fischer N., Mattei MG., Stévenin J., Fuchs JP.The human hnRNP-M proteins: structure and relation with early heat shock-induced splicing arrest and chromosome mapping.Nucleic Acids Res.1996;24,2535–2542.
68. Datar KV, Dreyfuss G., Swanson MS. The human hnRNP M proteins: identification of a methionine/arginine-rich repeat motif in ribonucleoproteins.Nucleic Acids Res.1993; 21,439–446.
69. Morohoshi F., Ootsuka Y., Arai K., Ichikawa H., Mitani S., Munakata N., Ohki M. Genomic structure of the human RBP56/hTAFII68 and FUS/TLS genes, Gene.1998; 221,191–198.
70. Mourelatos Z., Abel L., Yong J., Kataoka N., Dreyfuss G. SMN interacts with a novel family of hnRNP and spliceosomal proteins. EMBO J.2001;20,5443–5452.
71. Hassfeld W., Chan EK., Mathison DA., Portman D., Dreyfuss G., Steiner G., Tan EM. Molecular definition of heterogeneous nuclear ribonucleoprotein R (hnRNP R) using autoimmune antibody: immunological relationship with hnRNP P.Nucleic Acids Res.1998;26,439–445.
72. Fackelmayer FO.,Richter A.Purification of two isoforms of hnRNP-U and characterization of their nucleic acid binding activity. Biochemistry. 1994;33,10416– 10422.
73. Iwanaga K.,Sueoka N.,Sato A.,Hayashi S.,Sueoka E. Heterogeneous nuclear ribonucleoprotein B1 protein impairs DNA repair mediated through the inhibition ofDNA-dependent protein kinase activity.Biochem. Biophys. Res. Commun.2005;333, 888–895.
74. Pio R.,Zudaire I.,Pino I.,Casta?o Z.,Zabalegui N.,Vicent S.,Garcia-Amigot F.,Odero M D., Lozano MD., Garcia-Foncillas J., Calasanz MJ., Montuenga LM. Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer.Cancer Res. 2004;64,4171–4179.
75. Wu S., Sato M., Endo C., Sakurada A., Dong B., Aikawa H., Chen Y., Okada Y., Matsumura Y., Sueoka E., Kondo T. HnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung.Lung Cancer.2003;41,179–186.
76. Snead DR., Perunovic B., Cullen N., Needham M., Dhillon DP., Satoh H., Kamma H. HnRNP B1 expression in benign and malignant lung disease. J. Pathol. 2003;200,88–94.
77. Sueoka E., Sueoka N., Goto Y., Matsuyama S., Nishimura H., Sato M., Fujimura S., Chiba H.,Fujik H.Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasi. Cancer Res.2001;61,1896–1902.
78. Tominaga M, Sueoka N, Irie K, Iwanaga K, Tokunaga O, Hayashi S, Nakachi K, Sueoka E. Tominaga. M., Sueoka. N., Irie. K., Iwanaga. K., Tokunaga .O., Hayashi .S., Nakachi. K., Sueoka .E.Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRNP B1 combined with the cell cycle-related markers p16, cyclin D1, and Ki-67.Lung Cancer.2003;40,45–53.
79. Pino I., Pío R.,Toledo G.,Zabalegui N., Vicent S., Rey N., Lozano MD., Torre W., García-Foncillas J., Montuenga LM.Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer.Lung Cancer.2003;41,131–143.
80. Ushigome M., Ubagai T., Fukuda H., Tsuchiya N., Sugimura T., Takatsuka J.,Nakagama H. Up-regulation of hnRNP A1 gene in sporadic human colorectal cancers.Int. J. Oncol.2005;26,635–640.
81. Zhou J., Allred DC., Avis I., Martínez A., Vos MD., Smith L., Treston AM., Mulshine JL.Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res. Treat. 2001;66, 217–224.
82. Yan-Sanders Y., Hammons GJ., Lyn-Cook BD. Increased expression of heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP) in pancreatic tissue from smokers and pancreatic tumor cells.Cancer Lett. 2002; 183,215-220.
83. Lee CH., Lum JH., Cheung BP., Wong MS., Butt YK., Tam M.F., Chan WY., Chow C., Hui PK., Kwok FS., Lo SC., Fan DM. Identification of the heterogeneous nuclear ribonucleoprotein A2/B1 as the antigen for the gastrointestinal cancer specific monoclonal antibody MG7.Proteomics .2005;5,1160–1166.
84. Bidot P., Morgan M., Zhukov T., Tannenbaum M., Tockman MS. Loss of heterogeneous ribonucleoprotein A(2)/B(1) expression in thyroid neoplasms.Endocr. Pract.2001; 7,157–161.
85. Matsuyama S., Goto Y., Sueoka N., Ohkura Y., Tanaka Y., Nakachi K., Sueoka E. Heterogeneous nuclear ribonucleoprotein B1 expressed in esophageal squamous cell carcinomas as a new biomarker for diagnosis. Jpn. J. Cancer Res.2000;91,658–663.
86. Tani H., Ohshima K., Haraoka S., Hamasaki M., Kamma H., Ikeda S., Kikuchi M. Overexpression of heterogeneous nuclear ribonucleoprotein B1 in lymphoproliferative disorders: high expression in cells of follicular center origin.Int. J. Oncol.2002; 21,957–963.
87. Tani H., Ohshima K., Haraoka S., Hamasaki M., Kamma H., Ikeda S., Kikuchi M. Reduced expression of heterogeneous nuclear ribonucleoprotein B1 in adult T-celllymphoma/leukemia.Int. J. Oncol.2003;22,529–534.
88. Goto Y., Sueoka E., Chiba H., Fujiki H.Significance of heterogeneous nuclear ribonucleoprotein B1 as a new early detection marker for oral squamous cell carcinoma.Jpn. J. Cancer Res.1999;90,1358–1363.
89. Pillai MR., Chacko P., Kesari LA., Jayaprakash PG., Jayaram HN., Antony AC. Expression of folate receptors and heterogeneous nuclear ribonucleoprotein E1 in women with human papillomavirus mediated transformation of cervical tissue to cancer.J. Clin. Pathol. 2003;56, 569–574.
90. Honoré B., Baandrup U., Vorum H. Heterogeneous nuclear ribonucleoproteins F and H/H′ show differential expression in normal and selected cancer tissues. Exp. Cell. Res.2004;294,199–209.
91. Rauch J., Ahlemann M., Schaffrik M., Mack B., Ertongur S., Andratschke M., Zeidler R., Lang S., Gires O. Allogenic antibody-mediated identification of head and neck cancer antigens. Biochem. Biophys. Res. Commun.2004;323,156–162.
92. Jin W., Mc Cutcheon IE., Fuller GN., Huang ES., Cote G.J. Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tractbinding protein in glioblastoma multiforme tumors.Cancer Res. 2000;60,1221–1224.
93. Ostrowski J., Bomsztyk K.Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation.Br. J. Cancer.2003;89, 1493–1501.
94. Tockman MS., Gupta PK., Myers JD., Frost JK., Baylin SB., Gold EB., Chase AM., Wilkinson PH., Mulshine JL. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection.J. Clin. Oncol. 1988;6,1685–1693.
95. Mulshine JL., Cuttitta F., Bibro M., Fedorko J., Fargion S., Little C., Carney DN., Gazdar AF., Minna JD. Monoclonal antibodies that distinguish non-small cell fromsmall cell lung cancer, J. Immunol. 1983;131, 497–502.
96. Zhou J., Mulshine JL., Unsworth EJ., Scott FM., Avis IM., Vos MD., Treston. AM. Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. J. Biol. Chem. 1996;271,10760–10766.
97. 李润生,操乐杰. 核内不均一核蛋白A2/ B1 在肺癌诊断上的进展. 国外医学内科学分册.2005;32(9),401-411.
98. Dreyfuss G., Matunis MJ., Pi?ol-Roma S., Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem. 1993;62,289-321.
99. Zhou J., Mulshine JL., Unsworth EJ., Scott FM., Avis IM., Vos MD., Treston AM. Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4.J Biol Chem. 1996 ;271,10760-10766.
100. Kamma H., Satoh H., Matusi M., Wu W.W., Fujiwara M., Horiguchi H. Characterization of hnRNP A2 and B1 using monoclonal antibodies: intracellular distribution and metabolism through cell cycle. Immunol Lett. 2001;76,49-54.
101. Kamma H., Fujimoto M., Fujiwara M., Matsui M., Horiguchi H., Hamasaki M., Satoh. H. Interaction of hnRNP A2/B1 isoforms with telomeric ssDNA and the in vitro function. Biochem Biophys Res Commun. 2001 ;280,625-630.
102. Man YG., Martinez A., Avis IM., Hong SH., Cuttitta F., Venzon DJ., Mulshine JL.Phenotypically different cells with heterogeneous nuclear ribonucleoprotein A2/B1 overexpression show similar genetic alterations. Am J Respir Cell Mol Biol. 2000 ;23,636-645.
103. Zhou J., Nong L., Wloch M., Cantor A., Mulshine JL., Tockman MS. Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellitealteration in non-small cell lung cancer. Lung Cancer. 2001;34,341-350.
104. Montuenga LM., Zhou J., Avis I., Vos M., Martinez A., Cuttitta F., Treston AM., Sunday M., Mulshine JL. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development. Am J Respir Cell Mol Biol. 1998 ;19,554-562.
105. Matsui M., Horiguchi H., Kamma H., Fujiwara M., Ohtsubo R.., Ogata T. Testis- and developmental stage-specific expression of hnRNP A2/B1 splicing isoforms, B0a/b. Biochim Biophys Acta. 2000 ;1493,33-40.
106. Pino I., Pío R., Toledo G., Zabalegui N., Vicent S., Rey N., Lozano M.D., Torre W., García-Foncillas J., Montuenga LM.Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer. 2003 ;41,131-143.
107. Satoh H., Ishikawa H., Kamma H., Yamashita YT., Sekizawa K. HnRNP A2/B1 proteins in nontumorous alveolar cells. Lung. 2003;181,219-225.
108. Sueoka N., Lee HY., Walsh GL., Hong WK., Kurie JM. Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells. Cancer Res. 1999 ;59,3838-44.
109. Snead DR., Perunovic B., Cullen N., Needham M., Dhillon DP., Satoh H., Kamma H. hnRNP B1 expression in benign and malignant lung disease. J Pathol. 2003 ;200,88-94.
110. Sueoka E., Sueoka N., Goto Y., Matsuyama S., Nishimura H., Sato M., Fujimura S., Chiba H., Fujiki H. Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia.Cancer Res. 2001;61,1896-1902.
111. Hamasaki M., Kamma H., Wu W., Kaneko S., Fujiwara M., Satoh H., Haraoka S., Kikuchi M., Shirakusa T. Expression of hnRNP B1 in four major histological types oflung cancers. Anticancer Res. 2001;21,979-984.
112. Fielding P., Turnbull L., Prime W., Walshaw M., Field JK. Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens: a clinical marker of early lung cancer detection. Clin Cancer Res. 1999 ; 5,4048-4052.
113. Wu S., Sato M, Endo C., Sakurada A., Dong B., Aikawa H., Chen Y., Okada Y., Matsumura Y., Sueoka E., Kondo T.hnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung. Lung Cancer. 2003 ;41,179-186.
114. Matsuyama S., Goto Y., Sueoka N., Ohkura Y., Tanaka Y., Nakachi K., Sueoka E.Heterogeneous nuclear ribonucleoprotein B1 expressed in esophageal squamous cell carcinomas as a new biomarker for diagnosis. Jpn J Cancer Res. 2000; 91,658-663.
115. Tominaga M., Sueoka N., Irie K., Iwanaga K., Tokunaga O., Hayashi S., Nakachi K., Sueoka E. Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRNP B1 combined with the cell cycle-related markers p16, cyclin D1, and Ki-67. Lung Cancer.2003 ;40,45-53.
116. Fleischhacker M., Beinert T., Ermitsch. M., Seferi D., Possinger K., Engelmann C., Jandrig B. Ann N Y Acad Sci. 2001 ;945,179-188.
117. Fujimoto N., Sueoka N., Sueoka E., Okabe S., Suganuma M., Harada M., Fujiki H.Lung cancer prevention with (-)-epigallocatechin gallate using monitoring by heterogeneous nuclear ribonucleoprotein B1. Int J Oncol. 2002 ;20,1233-1239.
118. Fujiki H., Suganuma M., Okabe S., Sueoka E., Sueoka N., Fujimoto N., Goto Y., Matsuyama S., Imai K., Nakachi K. Cancer prevention with green tea and monitoring by a new biomarker, hnRNP B1. Mutat Res. 2001; 480-481,299-304. Review.
119. 杨礼富. 蛋白质组学研究技术与展望. 热带农业科学. 2007; 27(2),58-62.
120. Zhu H., Snyder., Michael. "Omic" approaches for unraveling signaling networks. Current Opinion in Cell Biology.2002;14,173-179.
121. 徐丽,刘松财,张永亮.蛋白质组学的研究进展.现代农业科技.2007; 22 ,149-150,153.
122. 李伯良, 李林, 吴家睿.功能蛋白质组学.生物工程学报.2000;27 (3) ,227- 231.
123. 李伯良.功能蛋白组学.生命的化学.1998;18( 6) ,1 - 4.
124. 俞利荣, 曾嵘, 夏其昌.蛋白质组研究技术及其进展.生命的化学. 1998 ;18( 6) , 4- 9.
125. Manabe Takashi. Combination of electrophoretic techniques for comprehensive analysis of complex protein systems. Electrophoresis. 2000;21, 1116-1122.
126. Li LJ, Garden RW, Sweedler JV. Single-cell MALDI: a new tool for direct peptide profiling. Trends in Biotechnology.2000;18, 151-160.
127. Scalf M., Westphall MS., Smith LM. Charge reduction electrospray mass spectrometry. Analytical Chemistry.2000; 72,52- 60.
128. Yates III John R. Mass spectrometry and the age of the proteome. Journal of Mass Spectrometry.1998; 33, 1- 19.
129. Godovac-Zimmermann J., Brown LR. Perspectives for mass spectrometry and functional proteomics. Mass Spectrometry Reviews. 2001;20,1- 57.
130. Mann M., Hendrickson RC., Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annual Review of Biochemistry. 2001;70,437-473.
131. James P., Quadroni M., Carafoli E., Gonnet G. Protein identification by mass profile fingerprinting. Biochemical and Biophysical Research Communications. 1993;195,58- 64.
132. Pappin DJ., Hojrup P., Bleasby AJ. Rapid identification of proteins by peptide-mass fingerprinting. Current Biology.1993; 3,327-332.
133. Yates JR 3rd., Speicher S., Griffin PR., Hunkapiller T. Peptide mass maps: a highly informative approach to protein identification. Analytical Biochemistry. 1993;214, 397-408.
134. 王京兰,万晶宏,罗凌,熊少祥,王光辉,贺福初,钱小红.蛋白质组研究中肽质量指纹谱鉴定方法的建立及应用. 生物化学与生物物理学报. 2000;32(4),373-378.
135. Graves PR., Haystead TAJ. Molecular biologist's guide to proteomics. Microbiology and Molecular Biology Reviews. 2002;66,39-63.
136. Blackstock WP., Weir MP. Proteomics: quantitative and physical mapping of cellular proteins. Trends in Biotechnology.1999;17, 121-127.
137. Uetz P., Giot L., Cagney G., Mansfield TA., Judson RS., Knight JR., Lockshon. D., Narayan V., Srinivasan M., Pochart P., Qureshi-Emili A., Li Y., Godwin B., Conover D., Kalbfleisch T., Vijayadamodar G., Yang M., Johnston. M., Fields S., Rothberg JM. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature.2000;403,623-627.
138. Gygi SP., Rist B., Gerber SA., Turecek F., Gelb MH., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnology. 1999;17,994-999.
139. Salamon Z., Brown MF., Tollin G. Plasmon resonance spectroscopy: probing molecular interactions within membranes. Trends in Biochemical Sciences. 1999;24,213- 219.
140. Nieba L., Nieba-Axmann SE., Persson A., H?m?l?inen M., Edebratt F., Hansson A., Lidholm J., Magnusson. K., Karlsson A.F., Plückthun A. BIACORE analysis of histidine-tagged proteins using a chelating NTA sensor chip. Analytical Biochemistry, 1997;252,217-228.
141. Rossignol M. Analysis of the plant proteome.Current Opinion in Biotechnology. 2001; 12,131-134.
142. 贾宇峰, 林秋霞,郭尧君,郭鹞,刘少君.蛋白质双向电泳图像分析. 生物化学与生物物理进展, 2001; 28 (2), 246-250.
143. 杨何义,应万涛,钱小红.蛋白质组技术的研究进展.自然科学进展. 2002; 12(1), 13-17.
144. Rabilloud T. Detecting proteins separated by 2-D gel electrophoresis. AnalyticalChemistry. 2000; 72,48-55.
145. 成海平, 钱小红. 蛋白质组研究的技术体系及其进展.生物化学与生物物理进展, 2000; 27(6), 584-588.
146. Snyder M., Kumar A. Yeast genomics: past, present, and future promise. Functional & Integrative Genomics. 2002; 2,135-137.
147. Von MC., Krause R., Snel. B., Cornell. M., Oliver. SG., Fields S., Bork P. Comparative assessment of large-scale data sets of protein-protein interactions. Nature.2002; 417,399-403.
148. Stagljar I., Korostensky C., Johnsson N., te Heesen S.A new genetic system based on split-ubiquitin for the analysis of interactions between membrane proteins in vivo. Proceedings of the National Academy of Sciences of the United States of America.1998;95,5187-5192.
149. 汪泱,张叔人,何祖根,张友会. 免疫球蛋白样分子在非淋巴细胞肿瘤中的表达.中国肿瘤生物治疗杂志.2000; 7(3), 227-228.
150. 邱晓彦, 杨贵贞. 恶性肿瘤细胞内存在免疫球蛋白样物质. 白求恩医科大学学报.1996 ; 22(6),572-575.
151. 邱晓彦,侯春梅,沈继铭,张叔人,唐佩弦,毛宁.HL260 细胞Ig 样蛋白的表达及IgH V2 D2J 序列分析. 中华血液杂志. 1999 ; 20(6),319-320.
152. 曹亚,孙毅,黄周琪.对鼻咽癌恶性转化基因Tx 表达的初步研究. 生物化学杂志.1995;11(4),381.
153. 胡维新, 曹亚, 黎民敬, 等. 人类鼻咽癌细胞株CNE2 的转化基因的一个EcoR Ⅰ片段的核苷酸序列分析. 生物化学杂志, 1993;9(3),331.
154. Yan Z., Yong-Guang T., Fei-Jun L., Fa-Qing T., Min T., Ya C. Interference effect of epigallocatechin-3-gallate on targets of nuclear factor kappaB signal transduction pathways activated by EB virus encoded latent membrane protein 1. Int J Biochem CellBiol. 2004;36,1473-1481.
155. Kimoto Y. Expression of heavy-chain constant region of immunoglobulin and T-cell receptor gene transcripts in human non-hematopoietic tumor cell lines. Genes Chromosomes Cancer. 1998 ;22,83-86.
156. Kimoto Y. A single human cell expresses all messenger ribonucleic acids: the arrow of time in a cell. Mol Gen Genet. 1998 ;258,233-239.
157. Magor. BG., Ross DA., Pilstr?m L., Warr GW.Transcriptional enhancers and the evolution of the IgH locus.Immunol Today. 1999 ;20,13-17.
158. 甘涛,王一平,肖文君,刘小菁,强鸥,谭卫东,王 淼.抗-Hp CagA IgG 血清对胃癌细胞的增殖作用及对癌基因表达的影响.华西医大学报.2002;33(3), 401 -403.
159. Janulaityte-Günther D., Kupcinskas L., Pavilonis A., Valuckas K., Wadstr?m T., Andersen LP. Combined serum IgG response to Helicobacter pylori VacA and CagA predicts gastric cancer.FEMS Immunol Med Microbiol.2007;50,220-225.
160. Knekt P., Teppo L., Aromaa A., Rissanen H., Kosunen TU. Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer. 2006 ;119,702-705.
161. Atalay C., Atalay G., Altinok M. Serum Helicobacter pylori IgG and IgA levels in patients with gastric cancer. Neoplasma. 2003;50,185-190.
162. Klaamas K., Held M., Wadstr?m T., Lipping A., Kurtenkov O. IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting. Int J Cancer. 1996 ;67,1-5.
163. 叶月芳 , 周韧 . 只有 B 淋巴细胞才能表达免疫球蛋白? 国外医学 : 免疫学分册.2004;27(1),12-15.
164. 邱晓彦,侯春梅,李秀森.多种肿瘤传代细胞中lg样物质存在与检测.癌症.1999;18(2), 180-181, 184.
165. Hu JB.,Zheng S.,Deng YC.Expression of a novel immunoglobulin geneSNC73 in human cancer and none-cancerous tissues.world J Gastroenterol.2003;9(5),1054-1057.
166. 吴翰桂,郑树.大肠癌相关新基因SNC66在大肠癌组织及正常粘膜中表达的比较研究.南开大学学报(自然科学).2002;35(1),33-37.
167. Li M., Ren W., Weng X.X., Liao W., Xia LQ., Deng X., Cao Y.Nucleotide sequence analysis of a transforming gene isolated from nasopharyngeal carcinoma cell line CNE2: an aberrant human immunoglobulin kappa light chain which lacks variable region. DNA Seq. 2001 ;12,331-335.
168. 杨少波,王孟薇,尤纬缔.胃癌细胞中免疫球蛋白轻链Igκ和Igλ的共同表达.中华肿瘤杂志.2002;24(5),465-466.
169. Krangel MS. Gene segment selection in V(D)J recombination: accessibility and beyond.Nat Immunol. 2003 ;4,624-630.
170. Benito C., Gomis R., Fernández-Alvarez J., Usac EF., Gallart T. Transcript expression of two Iglambda rearrangements and RAG-1/RAG-2 in a mature human B cell producing IgMlambda islet cell autoantibody. J Clin Immunol. 2003 ;23,107-118.
171. Sekiguehi DR.,Eisenberg RA.,Weigert M.Secondary heavy chain rearrangement:a mechanism for generating anti-double-stranded DNA B cells.J ExpMed. 2003; 197,27-39.
172. Giachino C.,Padovan E.,Lanzavecchia A.Reexpression of RAG-1 and RAG-2 genes and evidence for secondary rearrangements in human germinal center B lymphoeytes. Fur J Immunol.1998;28,3506-3513.
173. Lantelme E., Palermo B., Granziero L., Mantovani S., Campanelli R., Monafo V., Lanzavecchia A., Giachino C. Cutting edge: recombinase-activating gene expression and V(D)J recombination in CD4+CD3 low mature T lymphocytes. J Immunol. 2000; 164,3455-3459.
174. Tran AH., Mrkobrada M., Wu GE. Identification of potential regulatory elements in the human immunoglobulin loci. Blood Cells Mol Dis. 2002 ;29, 86-93.
175. 戴晓天, 杨和平. hnRNP A2/ B1 在肺癌组织中的表达及其临床意义. 第三军医大学学报.2005; 27(5),418-421.
176. Rosenfeld J., Capdevielle J., Guillemot JC., Ferrara P. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis.Anal Biochem. 1992 ;203,173-179.
177. Wolkersd?rfer GW., Haase M., Morgner A., Baretton G., Miehlke S. Monoclonal gammopathy of undetermined significance and Russell body formation in Helicobacter pylori gastritis. Helicobacter. 2006 ; 11,506-510.
178. Vordermark D., Said HM.,Katzer A., Kuhnt T.,H?nsgen G., Dunst J. Flentje M., Bache M. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system.BMC Cancer.2006;6,207.
179. Ewan KL.,Li X.,Cheikh SBK.,Pedneault M.,Chu CW. Human kallikrein 10 ELISA development and validation in breast cancer sera.Clin Biochem. 2007; 40, 1057-1062.
180. Scholler N.,Crawford M.,Sato A.,Drescher CW.,O'Briant KC.,Kiviat N.,Anderson GL., Urban N.Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res.2006;12,2117-2124.
181. Konishi N.,Matsumoto K.,Hiasa Y.,Kitahori Y.,Hayashi I.,Matsuda H. Tissue and serum pepsinogen I and II in gastric cancer identified using immunohistochemistry and sensitive ELISA.J Clin Pathol.1995 ;48,364-367.
182. 马大昌,武力,王育成,马宇光,张煦. CXCR4 单克隆抗体对人乳腺癌细胞 MCF -7 凋亡的影响. 现代肿瘤医学.2006;14(11),1383-1385.
183. Yoshida M, Yasuda T, Hiramitsu T, Ito H, Nakamura T. Induction of apoptosis by anti-CD44 antibody in human chondrosarcoma cell line SW1353. Biomed Res. 2008 ;29,47-52.
184. Li SL, Ma YF, Liu GC, Zhang J, Bai HL, Liu YJ.Leukemic cell apoptosis induced by anti-human DR5 monoclonal antibody mDRA-6. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007 ;23,754-756.
185. 李耕,张学庸,樊代明,胡家露. 单克隆抗体 MG7 抑制胃癌细胞粘附和运动功能的初步研究. 现代肿瘤杂志. 1994;2(1),20-21.
2. Fan DM., Zhang XY., Chen XT., Mou ZX., Hu JL., Qiao TD., Chen BJ.,Wang JY., Zhang ZQ.,Gao ZQ.,Establishment of four monoclonal antibodies to a poorly differentiated gastric cancer cell line MKN-46-9 and immuno-histochemical study on their corresponding antigens. Medical Journal of Chinese People's Liberation Army. 1988; 13, 488-489.
3. Ren J., Fan DM., Zhou SJ., Zhang XY., Yang AG., Li MF., Chen Z. Establishment of immuno-PCR technique for the detection of tumor associated antigen MG7-Ag on the gastric cancer cell line. Chinese Journal of Oncology. 1994 ;16,247-250.
4. Ren. J., Chen Z., Juan SJ., Yong XY., Pan BR., Fan DM. Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique. Cancer.2000; 88, 280–285.
5. Huang LQ., Guo GH.,Cai J.,Ren J.Clinical significance of serum MG7Ag in gastric cancer and precancerous lesion.Journal of Postgraduates of Medicine (Surgery Edition) .2004; 27 ,21-22.
6. Guo DL., Ning PF., Wang L., Yuan Y. Dynamic expression of antigen MG7 in the gastric cancer and gastric precancerous lesions. Zhonghua Liu Xing Bing Xue Za Zhi. 2003 ;24(6),494-497.
7. Guo DL, Dong M, Wang L, Sun LP, Yuan Y. Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori -associated gastric diseases. World J Gastroenterol. 2002;8(6),1009-1013.
8. Zhang X., Hong L., Chan WY., Qiao T., Chen B.,Liu Y.,Fan D.Expression of MG7-Ag in patients with gastric cancer correlates with weaker T cell immune response and moreproinflammatory cytokine secretion. Biochem Cell Biol.2006 ;84,135-141.
9. 张裕民,邓敬兰,彭勇,秦云才,杨思齐.胃癌131 I-MG7 瘤内注射药代动力学及辐射剂量估算.中华核医学杂志.1998;18,61-62.
10. 邓敬兰,周润锁,张裕民,周绍娟,陈敏,林国成,彭勇,秦云才,杨思齐.131I-抗胃癌单抗在胃癌患者体内的动态分布观察. 中华核医学杂志. 1997 ;17, 114-115.
11. 秦云才,彭勇,杨思齐,邓敬兰,周雯,仇凯,周润锁,张裕民,王培杰. 131 I-MG7胃癌内注射治疗的临床研究.中华消化内镜杂志.1998;15,136-138.
12. 何凤田,聂勇战,韩者艺,陈宝军,乔太东,樊代明. 胃癌单克隆抗体MG7的噬菌体呈现型抗独特型单链抗体ScFv的制备.中华医学杂志.2001;81(1),33-36.
13. Fengtian H., Yongzhan N., Baojun C., Taidong Q., Zheyi H., Daiming F. Production of phage-displayed anti-idiotypic antibody single chain variable fragments to MG7 monoclonal antibody directed against gastric carcinoma. Chin Med Sci J. 2002 ;17,215-219.
14. 喻召才,丁杰,樊代明,张学庸. 利用噬菌体呈现技术筛选单抗MG7 ScFv 片段.细胞与分子免疫学杂志. 2001;17(6),564-565.
15. Zhaocai Y., Jie D., Borong P., Daiming F., Xueyong Z. Expression and bioactivity identification of soluble MG7 scFv . World J Gastroenterol. 2002;8,99-102.
16. 喻召才, 丁杰, 樊代明, 张学庸. MG7 胞内抗体的表达及活性鉴定.免疫学杂志.2001;17(6),410-412.
17. 徐立,乔泰东,陈宝军,欧阳为明,丁杰,张庆华,周隽,吴昕彦,金伯泉,樊代明.胃癌相关抗原MG7-Ag 模拟肽表位的筛选及测序分析. 中华医学杂志.2000 ;80(4),304-307.
18. 韩全利,丁杰,巩爱春,喻召才,乔泰东,陈宝军,张学庸,樊代明.胃癌相关抗原表位模拟短肽的筛选. 细胞与分子免疫学杂志.2003 ;19 (3),308-310.
19. 韩全利,丁杰,何凤田,喻召才,樊代明. 胃癌相关抗原模拟表位的筛选及鉴定. 中华微生物学和免疫学杂志.2001;21(2),164-165.
20. 韩全利,丁杰,喻召才, 何凤田,樊代明. 应用噬菌体肽库筛选胃癌相关抗原模拟表位. 第四军医大学学报.2000;21 (9),1162-1164.
21. Li Xu., Boquan Jin., Daiming Fan. Selection and Identification of Mimic Epitopes for Gastric Cancer-associated Antigen MG7-Ag. Molecular Cancer Therapeutics. 2003;2,301–306.
22. 孟繁平,丁杰, 喻召才,韩全利,郭长存,刘娜,樊代明.胃癌MG7-Ag 模拟表位减毒鼠伤寒沙门菌活菌疫苗研制及免疫效果. 中华消化杂志.2005;25(9),546-549.
23. 徐立, 徐宏勇,马福成,金伯泉,樊代明. 噬菌体抗原模拟表位的免疫原性研究.中华肿瘤杂志. 2001;23(3),187-189.
24. 郭长存,丁杰,喻召才,韩全利,孟繁平,樊代明. 基于胃癌MG7-Ag 模拟表位基因疫苗的构建. 第四军医大学学报.2002;23(2),107-110.
25. 郭长存,丁杰,喻召才,韩全利,孟繁平,刘娜,樊代明. 胃癌MG7-Ag 模拟表位口服DNA疫苗的研制.中华肿瘤杂志.2002 ;24(2),110-113.
26. 师瑞,吴开春,吴道澄,宁晓暄,林涛,樊代明.胃癌特异性纳米疫苗的制备及其生物学活性的研究. 中国肿瘤生物治疗杂志.2005;12(1),9-12.
27. Shi R., Hong L., Wu D., Ning X, Chen Y, Lin T, Fan D, Wu K.Enhanced Immune Response to Gastric Cancer Specific Antigen Peptide by Coencapsulation with CpG Oligodeoxynucleotides in Nanoem sion. Cancer Biology & Therapy. 2005;4(2), 218-224.
28. Chen Y, Wu K, Guo C, Liu C, Han S, Lin T, Ning X, Shi R, Shi Y, Fan D. A novel DNA vaccine containing four mimicry epitopes for gastric cancer. Cancer Biol Ther.2005; 4(3),308-312.
29. Zhang JR., Zhang XY., Chen XT., Gu TJ.,Zhang. DS.A new gastric cancer antigen associated glycolipid and glycoprotein.J Med Coll PLA.1990; 5,63-65.
30. 丁杰,王福安,张学庸.胃癌单克隆抗体MG7相应抗原与DBA受体在胃癌细胞中的电镜双标记定位.第四军医大学学报.1993;14 (3), 172-174.
31. 耿明,刘晓红,张培忠,张福洲,郝志军.胃癌超微结构与M G7-Ag分布的关系. 实用癌症杂志.1997;12(3),189-190.
32. Liu J., Lin Y., Zhang L.Detection of MG7 antigen expression in predicting high-risk in gastric cancer by automatic image analysis. Zhonghua Yu Fang Yi Xue Za Zhi. 1996 ;30(5),286-288.
33. Liu J., Hu JL., Zhang XY., Qiao TD., Chen XT., Wu KC., Ding J., Fan DM. The value of MG7 antigen in predicting cancerous change in dysplastic gastric mucosa. Int J Clin Pract. 2002 ;56(3),169-72.
34. 扎西措姆,吴开春,乔泰东,申慧琴,杜安春,索朗多杰,黄跃,樊代明.藏族和汉族胃癌相关抗原MG7-Ag表达差异的分析. 中华内科杂志.2004; 43(4), 643-646.
35. Yunping Z.,Yaoguang J., Ruwen W.,Xiushan Z.,Xin W., Bin J., Yuanyuan L.,Taidong Q.,Liu H., Daiming F.Expression and Prognostic Value of MG7-Ag in Patients With Surgically Resectable Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2007 ;14(9),2621-2627.
36. 韩英,时永全,聂永战,何风田,樊代明.MG7Ag 在胃癌细胞系SGC 7901 及其耐药亚系中的表达及功能.解放军医学杂志.2001 ;26 (6), 396-398.
37. 扎西措姆,吴开春,韩霜,潘阳林,韩者艺,申慧琴,樊代明.胃癌及非癌组织中环氧合酶-2 和人胃癌相关MG7 -Ag表达及意义.中华消化杂志.2004 ;24(11), 643- 646.
38. 赵斌燕 ,齐峰. Decorin因子对人胃癌细胞及其表达的MG7蛋白的作用.中华医学研究杂志. 2006;6(1),19-20.
39. 侯云修, 王巧银.MG7-Ag与AgNOR联用鉴别胃癌与癌前病变.西安医科大学学报.1998;19(3),428-430.
40. 金国元,孟迟,蒋敬庭,邓海峰. 血清MG7-Ag 、CA19-9 和IAP 联合检测对胃癌的诊断价值. 苏州医学院学报.2001 ;21 (1),72-73.
41. 左国庆,王景,沈鼎明.血清MG7-Ag和TAG-72 对胃癌的诊断价值.四川医学.2000 ;21 (1),25-26.
42. 刘军,左国庆.血清MG7-Ag和TAG-72在胃癌诊断中的应用.实用医学杂志.1999 ;15 (11),895-896.
43. 李新华,胡家露,陈铭声,林国成. 血清肿瘤标志物MG7Ag ,TAG72 ,CA19-9诊断胃癌的前瞻性对照研究.解放军医学杂志.1996;21(5),326-329.
44. Carpenter B., MacKay C., Alnabulsi A., MacKay M., Telfer C., Melvin WT., Murray GI.The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta. 2006 ;1765,85-100.
45. Choi YD., Dreyfuss G. Isolation of the heterogeneous nuclear RNA–ribonucleoprotein complex (hnRNP): a unique supramolecular assembly. Proc. Natl. Acad. Sci. U. S. A. 1984; 81,7471–7475.
46. Pi?ol-Roma S.,Choi YD.,Matunis MJ.,Dreyfuss G. Immunopurification of heterogeneous nuclear ribonucleoprotein particles reveals an assortment of RNA- binding proteins.Genes Dev. 1988;2, 215–227.
47. Dreyfuss G., Matunis MJ., Pi?ol-Roma S., Burd CG. HnRNP proteins and the biogenesis of mRNA, Annu. Rev. Biochem. 1993;62,289–321.
48. Saccone S., Biamonti G., Maugeri S., Bassi MT., Bunone G., Riva S., Della VG. Assignment of the human heterogeneous nuclear ribonucleoprotein A1 gene (hnRNP A1) to chromosome 12q13.1 by cDNA competitive in situ hybridization. Genomics. 1992;12,171–174.
49. Biamonti G., Buvoli M., Bassi MT., Morandi C., Cobianchi F., Riva S. Isolation of an active gene encoding human hnRNP protein A1. Evidence for alternative splicing, J. Mol. Biol.1989;207,491–503.
50. Buvoli M., Biamonti G., Tsoulfas P., Bassi MT., Ghetti A., Riva S., Morandi C. cDNAcloning of human hnRNP protein A1 reveals the existence of multiple mRNA isoforms.Nucleic Acids Res.1988;16,3751–3770.
51. Biamonti G., Ruggiu M., Saccone S., Della VG., Riva S. Two homologous genes, originated by duplication, encode the human hnRNP proteins A2 and A1. Nucleic Acids Res. 1994;22,1996–2002.
52. Burd CG., Swanson. MS., G?rlach M., Dreyfuss G..Primary structures of the heterogeneous nuclear ribonucleoprotein A2, B1, and C2 proteins: a diversity of RNA binding proteins is generated by small peptide inserts. Proc. Natl. Acad. Sci U. S. A.1989;86, 9788–9792.
53. Swanson MS., Nakagawa TY., LeVan K., Dreyfuss G. Primary structure of human nuclear ribonucleoprotein particle C proteins:conservation of sequence and domain structures in heterogeneous nuclear RNA, mRNA, and pre-rRNA-binding proteins. Mol. Cell. Biol.1987;7,1731–1739.
54. Dempsey LA., Li MJ., DePace A., Bray-Ward P., Maizels N. The human HNRPD locus maps to 4q21 and encodes a highly conserved protein.Genomics. 1998;49, 378–384.
55. Wagner BJ., DeMaria CT., Sun Y., Wilson GM.,Brewer G. Structure and genomic organization of the human AUF1 gene: alternative premRNA splicing generates four protein isoforms.Genomics.1998;48,195–202.
56. Makeyev AV., Chkheidze AN., Liebhaber SA.A set of highly conserved RNA- binding proteins, alphaCP-1 and alphaCP-2, implicated in mRNA stabilization, are coexpressed from an intronless gene and its intron-containing paralog.J. Biol. Chem.1999; 274, 24849–24857.
57. Honoré B., Rasmussen HH., Vorum H., Dejgaard K., Liu X., Gromov P., Madsen P., Gesser B., Tommerup N., Celis JE.Heterogeneous nuclear ribonucleoproteins H, H′, and F are members of a ubiquitously expressed subfamily of related but distinct proteinsencoded by genes mapping to different chromosomes.J. Biol. Chem.1995; 270, 28780– 28789.
58. Soulard M., Della VV., Siomi MC., Pi?ol-Roma S., Codogno P., Bauvy C., Bellini M., Lacroix JC., Monod G ., Dreyfuss. G . HnRNP G: sequence and characterization of a glycosylated RNA-binding protein. Nucleic Acids Res. 1993;21, 4210–4217.
59. Romanelli MG.,Lorenzi P.,Morandi C.Organization of the human gene encoding heterogeneous nuclear ribonucleoprotein type I (hnRNP I) and characterization of hnRNP I related pseudogene. Gene .2000;255,267–272.
60. Patton JG., Mayer SA., Tempst P., Nadal-Ginard B.Characterization and molecular cloning of polypyrimidine tract-binding protein: a component of a complex necessary for pre-mRNA splicing, Genes Dev.1991;5,1237–1251.
61. Ghetti A., Pi?ol-Roma S., Michael WM., Morandi C., Dreyfuss G. HnRNP I, the polypyrimidine tract-binding protein: distinct nuclear localization and association with hnRNAs. Nucleic Acids Res.1992;20, 3671–3678.
62. Mahé D., M?hl P., Gattoni R., Fischer N., Mattei MG., Stévenin J., Fuchs JP. Cloning of human 2H9 heterogeneous nuclear ribonucleoproteins. Relation with splicing and early heat shock-induced splicing arrest. J. Biol. Chem.1997; 272,1827–1836.
63. Honoré B.The hnRNP 2H9 gene, which is involved in the splicing reaction, is a multiply spliced gene.Biochim. Biophys. Acta. 2000;1492,108–119.
64. Dejgaard K., Leffers H., Rasmussen HH., Madsen P., Kruse TA., Gesser B., Nielsen H., Celis JE.Identification, molecular cloning, expression and chromosome mapping of a family of transformation upregulated hnRNP-K proteins derived by alternative splicing.J. Mol. Biol.1994;236,33–48.
65. Pi?ol-Roma S., Swanson MS., Gall JG., Dreyfuss G.A novelheterogeneous nuclear RNP protein with a unique distribution on nascent transcripts. J. Cell. Biol.1989;109,2575–2587.
66. Blanck O., Perrin C., Mziaut H., Darbon H., Mattei MG., Miquelis R. Molecular cloning, cDNA analysis, and localization of a monomer of the N-acetylglucosamine- specific receptor of the thyroid, NAGR1, to chromosome 19p13.3-13.2.Genomics. 1994;21, 18–26.
67. Gattoni R., Mahé D., M?hl P., Fischer N., Mattei MG., Stévenin J., Fuchs JP.The human hnRNP-M proteins: structure and relation with early heat shock-induced splicing arrest and chromosome mapping.Nucleic Acids Res.1996;24,2535–2542.
68. Datar KV, Dreyfuss G., Swanson MS. The human hnRNP M proteins: identification of a methionine/arginine-rich repeat motif in ribonucleoproteins.Nucleic Acids Res.1993; 21,439–446.
69. Morohoshi F., Ootsuka Y., Arai K., Ichikawa H., Mitani S., Munakata N., Ohki M. Genomic structure of the human RBP56/hTAFII68 and FUS/TLS genes, Gene.1998; 221,191–198.
70. Mourelatos Z., Abel L., Yong J., Kataoka N., Dreyfuss G. SMN interacts with a novel family of hnRNP and spliceosomal proteins. EMBO J.2001;20,5443–5452.
71. Hassfeld W., Chan EK., Mathison DA., Portman D., Dreyfuss G., Steiner G., Tan EM. Molecular definition of heterogeneous nuclear ribonucleoprotein R (hnRNP R) using autoimmune antibody: immunological relationship with hnRNP P.Nucleic Acids Res.1998;26,439–445.
72. Fackelmayer FO.,Richter A.Purification of two isoforms of hnRNP-U and characterization of their nucleic acid binding activity. Biochemistry. 1994;33,10416– 10422.
73. Iwanaga K.,Sueoka N.,Sato A.,Hayashi S.,Sueoka E. Heterogeneous nuclear ribonucleoprotein B1 protein impairs DNA repair mediated through the inhibition ofDNA-dependent protein kinase activity.Biochem. Biophys. Res. Commun.2005;333, 888–895.
74. Pio R.,Zudaire I.,Pino I.,Casta?o Z.,Zabalegui N.,Vicent S.,Garcia-Amigot F.,Odero M D., Lozano MD., Garcia-Foncillas J., Calasanz MJ., Montuenga LM. Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer.Cancer Res. 2004;64,4171–4179.
75. Wu S., Sato M., Endo C., Sakurada A., Dong B., Aikawa H., Chen Y., Okada Y., Matsumura Y., Sueoka E., Kondo T. HnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung.Lung Cancer.2003;41,179–186.
76. Snead DR., Perunovic B., Cullen N., Needham M., Dhillon DP., Satoh H., Kamma H. HnRNP B1 expression in benign and malignant lung disease. J. Pathol. 2003;200,88–94.
77. Sueoka E., Sueoka N., Goto Y., Matsuyama S., Nishimura H., Sato M., Fujimura S., Chiba H.,Fujik H.Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasi. Cancer Res.2001;61,1896–1902.
78. Tominaga M, Sueoka N, Irie K, Iwanaga K, Tokunaga O, Hayashi S, Nakachi K, Sueoka E. Tominaga. M., Sueoka. N., Irie. K., Iwanaga. K., Tokunaga .O., Hayashi .S., Nakachi. K., Sueoka .E.Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRNP B1 combined with the cell cycle-related markers p16, cyclin D1, and Ki-67.Lung Cancer.2003;40,45–53.
79. Pino I., Pío R.,Toledo G.,Zabalegui N., Vicent S., Rey N., Lozano MD., Torre W., García-Foncillas J., Montuenga LM.Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer.Lung Cancer.2003;41,131–143.
80. Ushigome M., Ubagai T., Fukuda H., Tsuchiya N., Sugimura T., Takatsuka J.,Nakagama H. Up-regulation of hnRNP A1 gene in sporadic human colorectal cancers.Int. J. Oncol.2005;26,635–640.
81. Zhou J., Allred DC., Avis I., Martínez A., Vos MD., Smith L., Treston AM., Mulshine JL.Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res. Treat. 2001;66, 217–224.
82. Yan-Sanders Y., Hammons GJ., Lyn-Cook BD. Increased expression of heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP) in pancreatic tissue from smokers and pancreatic tumor cells.Cancer Lett. 2002; 183,215-220.
83. Lee CH., Lum JH., Cheung BP., Wong MS., Butt YK., Tam M.F., Chan WY., Chow C., Hui PK., Kwok FS., Lo SC., Fan DM. Identification of the heterogeneous nuclear ribonucleoprotein A2/B1 as the antigen for the gastrointestinal cancer specific monoclonal antibody MG7.Proteomics .2005;5,1160–1166.
84. Bidot P., Morgan M., Zhukov T., Tannenbaum M., Tockman MS. Loss of heterogeneous ribonucleoprotein A(2)/B(1) expression in thyroid neoplasms.Endocr. Pract.2001; 7,157–161.
85. Matsuyama S., Goto Y., Sueoka N., Ohkura Y., Tanaka Y., Nakachi K., Sueoka E. Heterogeneous nuclear ribonucleoprotein B1 expressed in esophageal squamous cell carcinomas as a new biomarker for diagnosis. Jpn. J. Cancer Res.2000;91,658–663.
86. Tani H., Ohshima K., Haraoka S., Hamasaki M., Kamma H., Ikeda S., Kikuchi M. Overexpression of heterogeneous nuclear ribonucleoprotein B1 in lymphoproliferative disorders: high expression in cells of follicular center origin.Int. J. Oncol.2002; 21,957–963.
87. Tani H., Ohshima K., Haraoka S., Hamasaki M., Kamma H., Ikeda S., Kikuchi M. Reduced expression of heterogeneous nuclear ribonucleoprotein B1 in adult T-celllymphoma/leukemia.Int. J. Oncol.2003;22,529–534.
88. Goto Y., Sueoka E., Chiba H., Fujiki H.Significance of heterogeneous nuclear ribonucleoprotein B1 as a new early detection marker for oral squamous cell carcinoma.Jpn. J. Cancer Res.1999;90,1358–1363.
89. Pillai MR., Chacko P., Kesari LA., Jayaprakash PG., Jayaram HN., Antony AC. Expression of folate receptors and heterogeneous nuclear ribonucleoprotein E1 in women with human papillomavirus mediated transformation of cervical tissue to cancer.J. Clin. Pathol. 2003;56, 569–574.
90. Honoré B., Baandrup U., Vorum H. Heterogeneous nuclear ribonucleoproteins F and H/H′ show differential expression in normal and selected cancer tissues. Exp. Cell. Res.2004;294,199–209.
91. Rauch J., Ahlemann M., Schaffrik M., Mack B., Ertongur S., Andratschke M., Zeidler R., Lang S., Gires O. Allogenic antibody-mediated identification of head and neck cancer antigens. Biochem. Biophys. Res. Commun.2004;323,156–162.
92. Jin W., Mc Cutcheon IE., Fuller GN., Huang ES., Cote G.J. Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tractbinding protein in glioblastoma multiforme tumors.Cancer Res. 2000;60,1221–1224.
93. Ostrowski J., Bomsztyk K.Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation.Br. J. Cancer.2003;89, 1493–1501.
94. Tockman MS., Gupta PK., Myers JD., Frost JK., Baylin SB., Gold EB., Chase AM., Wilkinson PH., Mulshine JL. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection.J. Clin. Oncol. 1988;6,1685–1693.
95. Mulshine JL., Cuttitta F., Bibro M., Fedorko J., Fargion S., Little C., Carney DN., Gazdar AF., Minna JD. Monoclonal antibodies that distinguish non-small cell fromsmall cell lung cancer, J. Immunol. 1983;131, 497–502.
96. Zhou J., Mulshine JL., Unsworth EJ., Scott FM., Avis IM., Vos MD., Treston. AM. Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. J. Biol. Chem. 1996;271,10760–10766.
97. 李润生,操乐杰. 核内不均一核蛋白A2/ B1 在肺癌诊断上的进展. 国外医学内科学分册.2005;32(9),401-411.
98. Dreyfuss G., Matunis MJ., Pi?ol-Roma S., Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem. 1993;62,289-321.
99. Zhou J., Mulshine JL., Unsworth EJ., Scott FM., Avis IM., Vos MD., Treston AM. Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4.J Biol Chem. 1996 ;271,10760-10766.
100. Kamma H., Satoh H., Matusi M., Wu W.W., Fujiwara M., Horiguchi H. Characterization of hnRNP A2 and B1 using monoclonal antibodies: intracellular distribution and metabolism through cell cycle. Immunol Lett. 2001;76,49-54.
101. Kamma H., Fujimoto M., Fujiwara M., Matsui M., Horiguchi H., Hamasaki M., Satoh. H. Interaction of hnRNP A2/B1 isoforms with telomeric ssDNA and the in vitro function. Biochem Biophys Res Commun. 2001 ;280,625-630.
102. Man YG., Martinez A., Avis IM., Hong SH., Cuttitta F., Venzon DJ., Mulshine JL.Phenotypically different cells with heterogeneous nuclear ribonucleoprotein A2/B1 overexpression show similar genetic alterations. Am J Respir Cell Mol Biol. 2000 ;23,636-645.
103. Zhou J., Nong L., Wloch M., Cantor A., Mulshine JL., Tockman MS. Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellitealteration in non-small cell lung cancer. Lung Cancer. 2001;34,341-350.
104. Montuenga LM., Zhou J., Avis I., Vos M., Martinez A., Cuttitta F., Treston AM., Sunday M., Mulshine JL. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development. Am J Respir Cell Mol Biol. 1998 ;19,554-562.
105. Matsui M., Horiguchi H., Kamma H., Fujiwara M., Ohtsubo R.., Ogata T. Testis- and developmental stage-specific expression of hnRNP A2/B1 splicing isoforms, B0a/b. Biochim Biophys Acta. 2000 ;1493,33-40.
106. Pino I., Pío R., Toledo G., Zabalegui N., Vicent S., Rey N., Lozano M.D., Torre W., García-Foncillas J., Montuenga LM.Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer. 2003 ;41,131-143.
107. Satoh H., Ishikawa H., Kamma H., Yamashita YT., Sekizawa K. HnRNP A2/B1 proteins in nontumorous alveolar cells. Lung. 2003;181,219-225.
108. Sueoka N., Lee HY., Walsh GL., Hong WK., Kurie JM. Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells. Cancer Res. 1999 ;59,3838-44.
109. Snead DR., Perunovic B., Cullen N., Needham M., Dhillon DP., Satoh H., Kamma H. hnRNP B1 expression in benign and malignant lung disease. J Pathol. 2003 ;200,88-94.
110. Sueoka E., Sueoka N., Goto Y., Matsuyama S., Nishimura H., Sato M., Fujimura S., Chiba H., Fujiki H. Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia.Cancer Res. 2001;61,1896-1902.
111. Hamasaki M., Kamma H., Wu W., Kaneko S., Fujiwara M., Satoh H., Haraoka S., Kikuchi M., Shirakusa T. Expression of hnRNP B1 in four major histological types oflung cancers. Anticancer Res. 2001;21,979-984.
112. Fielding P., Turnbull L., Prime W., Walshaw M., Field JK. Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens: a clinical marker of early lung cancer detection. Clin Cancer Res. 1999 ; 5,4048-4052.
113. Wu S., Sato M, Endo C., Sakurada A., Dong B., Aikawa H., Chen Y., Okada Y., Matsumura Y., Sueoka E., Kondo T.hnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung. Lung Cancer. 2003 ;41,179-186.
114. Matsuyama S., Goto Y., Sueoka N., Ohkura Y., Tanaka Y., Nakachi K., Sueoka E.Heterogeneous nuclear ribonucleoprotein B1 expressed in esophageal squamous cell carcinomas as a new biomarker for diagnosis. Jpn J Cancer Res. 2000; 91,658-663.
115. Tominaga M., Sueoka N., Irie K., Iwanaga K., Tokunaga O., Hayashi S., Nakachi K., Sueoka E. Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRNP B1 combined with the cell cycle-related markers p16, cyclin D1, and Ki-67. Lung Cancer.2003 ;40,45-53.
116. Fleischhacker M., Beinert T., Ermitsch. M., Seferi D., Possinger K., Engelmann C., Jandrig B. Ann N Y Acad Sci. 2001 ;945,179-188.
117. Fujimoto N., Sueoka N., Sueoka E., Okabe S., Suganuma M., Harada M., Fujiki H.Lung cancer prevention with (-)-epigallocatechin gallate using monitoring by heterogeneous nuclear ribonucleoprotein B1. Int J Oncol. 2002 ;20,1233-1239.
118. Fujiki H., Suganuma M., Okabe S., Sueoka E., Sueoka N., Fujimoto N., Goto Y., Matsuyama S., Imai K., Nakachi K. Cancer prevention with green tea and monitoring by a new biomarker, hnRNP B1. Mutat Res. 2001; 480-481,299-304. Review.
119. 杨礼富. 蛋白质组学研究技术与展望. 热带农业科学. 2007; 27(2),58-62.
120. Zhu H., Snyder., Michael. "Omic" approaches for unraveling signaling networks. Current Opinion in Cell Biology.2002;14,173-179.
121. 徐丽,刘松财,张永亮.蛋白质组学的研究进展.现代农业科技.2007; 22 ,149-150,153.
122. 李伯良, 李林, 吴家睿.功能蛋白质组学.生物工程学报.2000;27 (3) ,227- 231.
123. 李伯良.功能蛋白组学.生命的化学.1998;18( 6) ,1 - 4.
124. 俞利荣, 曾嵘, 夏其昌.蛋白质组研究技术及其进展.生命的化学. 1998 ;18( 6) , 4- 9.
125. Manabe Takashi. Combination of electrophoretic techniques for comprehensive analysis of complex protein systems. Electrophoresis. 2000;21, 1116-1122.
126. Li LJ, Garden RW, Sweedler JV. Single-cell MALDI: a new tool for direct peptide profiling. Trends in Biotechnology.2000;18, 151-160.
127. Scalf M., Westphall MS., Smith LM. Charge reduction electrospray mass spectrometry. Analytical Chemistry.2000; 72,52- 60.
128. Yates III John R. Mass spectrometry and the age of the proteome. Journal of Mass Spectrometry.1998; 33, 1- 19.
129. Godovac-Zimmermann J., Brown LR. Perspectives for mass spectrometry and functional proteomics. Mass Spectrometry Reviews. 2001;20,1- 57.
130. Mann M., Hendrickson RC., Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annual Review of Biochemistry. 2001;70,437-473.
131. James P., Quadroni M., Carafoli E., Gonnet G. Protein identification by mass profile fingerprinting. Biochemical and Biophysical Research Communications. 1993;195,58- 64.
132. Pappin DJ., Hojrup P., Bleasby AJ. Rapid identification of proteins by peptide-mass fingerprinting. Current Biology.1993; 3,327-332.
133. Yates JR 3rd., Speicher S., Griffin PR., Hunkapiller T. Peptide mass maps: a highly informative approach to protein identification. Analytical Biochemistry. 1993;214, 397-408.
134. 王京兰,万晶宏,罗凌,熊少祥,王光辉,贺福初,钱小红.蛋白质组研究中肽质量指纹谱鉴定方法的建立及应用. 生物化学与生物物理学报. 2000;32(4),373-378.
135. Graves PR., Haystead TAJ. Molecular biologist's guide to proteomics. Microbiology and Molecular Biology Reviews. 2002;66,39-63.
136. Blackstock WP., Weir MP. Proteomics: quantitative and physical mapping of cellular proteins. Trends in Biotechnology.1999;17, 121-127.
137. Uetz P., Giot L., Cagney G., Mansfield TA., Judson RS., Knight JR., Lockshon. D., Narayan V., Srinivasan M., Pochart P., Qureshi-Emili A., Li Y., Godwin B., Conover D., Kalbfleisch T., Vijayadamodar G., Yang M., Johnston. M., Fields S., Rothberg JM. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature.2000;403,623-627.
138. Gygi SP., Rist B., Gerber SA., Turecek F., Gelb MH., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnology. 1999;17,994-999.
139. Salamon Z., Brown MF., Tollin G. Plasmon resonance spectroscopy: probing molecular interactions within membranes. Trends in Biochemical Sciences. 1999;24,213- 219.
140. Nieba L., Nieba-Axmann SE., Persson A., H?m?l?inen M., Edebratt F., Hansson A., Lidholm J., Magnusson. K., Karlsson A.F., Plückthun A. BIACORE analysis of histidine-tagged proteins using a chelating NTA sensor chip. Analytical Biochemistry, 1997;252,217-228.
141. Rossignol M. Analysis of the plant proteome.Current Opinion in Biotechnology. 2001; 12,131-134.
142. 贾宇峰, 林秋霞,郭尧君,郭鹞,刘少君.蛋白质双向电泳图像分析. 生物化学与生物物理进展, 2001; 28 (2), 246-250.
143. 杨何义,应万涛,钱小红.蛋白质组技术的研究进展.自然科学进展. 2002; 12(1), 13-17.
144. Rabilloud T. Detecting proteins separated by 2-D gel electrophoresis. AnalyticalChemistry. 2000; 72,48-55.
145. 成海平, 钱小红. 蛋白质组研究的技术体系及其进展.生物化学与生物物理进展, 2000; 27(6), 584-588.
146. Snyder M., Kumar A. Yeast genomics: past, present, and future promise. Functional & Integrative Genomics. 2002; 2,135-137.
147. Von MC., Krause R., Snel. B., Cornell. M., Oliver. SG., Fields S., Bork P. Comparative assessment of large-scale data sets of protein-protein interactions. Nature.2002; 417,399-403.
148. Stagljar I., Korostensky C., Johnsson N., te Heesen S.A new genetic system based on split-ubiquitin for the analysis of interactions between membrane proteins in vivo. Proceedings of the National Academy of Sciences of the United States of America.1998;95,5187-5192.
149. 汪泱,张叔人,何祖根,张友会. 免疫球蛋白样分子在非淋巴细胞肿瘤中的表达.中国肿瘤生物治疗杂志.2000; 7(3), 227-228.
150. 邱晓彦, 杨贵贞. 恶性肿瘤细胞内存在免疫球蛋白样物质. 白求恩医科大学学报.1996 ; 22(6),572-575.
151. 邱晓彦,侯春梅,沈继铭,张叔人,唐佩弦,毛宁.HL260 细胞Ig 样蛋白的表达及IgH V2 D2J 序列分析. 中华血液杂志. 1999 ; 20(6),319-320.
152. 曹亚,孙毅,黄周琪.对鼻咽癌恶性转化基因Tx 表达的初步研究. 生物化学杂志.1995;11(4),381.
153. 胡维新, 曹亚, 黎民敬, 等. 人类鼻咽癌细胞株CNE2 的转化基因的一个EcoR Ⅰ片段的核苷酸序列分析. 生物化学杂志, 1993;9(3),331.
154. Yan Z., Yong-Guang T., Fei-Jun L., Fa-Qing T., Min T., Ya C. Interference effect of epigallocatechin-3-gallate on targets of nuclear factor kappaB signal transduction pathways activated by EB virus encoded latent membrane protein 1. Int J Biochem CellBiol. 2004;36,1473-1481.
155. Kimoto Y. Expression of heavy-chain constant region of immunoglobulin and T-cell receptor gene transcripts in human non-hematopoietic tumor cell lines. Genes Chromosomes Cancer. 1998 ;22,83-86.
156. Kimoto Y. A single human cell expresses all messenger ribonucleic acids: the arrow of time in a cell. Mol Gen Genet. 1998 ;258,233-239.
157. Magor. BG., Ross DA., Pilstr?m L., Warr GW.Transcriptional enhancers and the evolution of the IgH locus.Immunol Today. 1999 ;20,13-17.
158. 甘涛,王一平,肖文君,刘小菁,强鸥,谭卫东,王 淼.抗-Hp CagA IgG 血清对胃癌细胞的增殖作用及对癌基因表达的影响.华西医大学报.2002;33(3), 401 -403.
159. Janulaityte-Günther D., Kupcinskas L., Pavilonis A., Valuckas K., Wadstr?m T., Andersen LP. Combined serum IgG response to Helicobacter pylori VacA and CagA predicts gastric cancer.FEMS Immunol Med Microbiol.2007;50,220-225.
160. Knekt P., Teppo L., Aromaa A., Rissanen H., Kosunen TU. Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer. 2006 ;119,702-705.
161. Atalay C., Atalay G., Altinok M. Serum Helicobacter pylori IgG and IgA levels in patients with gastric cancer. Neoplasma. 2003;50,185-190.
162. Klaamas K., Held M., Wadstr?m T., Lipping A., Kurtenkov O. IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting. Int J Cancer. 1996 ;67,1-5.
163. 叶月芳 , 周韧 . 只有 B 淋巴细胞才能表达免疫球蛋白? 国外医学 : 免疫学分册.2004;27(1),12-15.
164. 邱晓彦,侯春梅,李秀森.多种肿瘤传代细胞中lg样物质存在与检测.癌症.1999;18(2), 180-181, 184.
165. Hu JB.,Zheng S.,Deng YC.Expression of a novel immunoglobulin geneSNC73 in human cancer and none-cancerous tissues.world J Gastroenterol.2003;9(5),1054-1057.
166. 吴翰桂,郑树.大肠癌相关新基因SNC66在大肠癌组织及正常粘膜中表达的比较研究.南开大学学报(自然科学).2002;35(1),33-37.
167. Li M., Ren W., Weng X.X., Liao W., Xia LQ., Deng X., Cao Y.Nucleotide sequence analysis of a transforming gene isolated from nasopharyngeal carcinoma cell line CNE2: an aberrant human immunoglobulin kappa light chain which lacks variable region. DNA Seq. 2001 ;12,331-335.
168. 杨少波,王孟薇,尤纬缔.胃癌细胞中免疫球蛋白轻链Igκ和Igλ的共同表达.中华肿瘤杂志.2002;24(5),465-466.
169. Krangel MS. Gene segment selection in V(D)J recombination: accessibility and beyond.Nat Immunol. 2003 ;4,624-630.
170. Benito C., Gomis R., Fernández-Alvarez J., Usac EF., Gallart T. Transcript expression of two Iglambda rearrangements and RAG-1/RAG-2 in a mature human B cell producing IgMlambda islet cell autoantibody. J Clin Immunol. 2003 ;23,107-118.
171. Sekiguehi DR.,Eisenberg RA.,Weigert M.Secondary heavy chain rearrangement:a mechanism for generating anti-double-stranded DNA B cells.J ExpMed. 2003; 197,27-39.
172. Giachino C.,Padovan E.,Lanzavecchia A.Reexpression of RAG-1 and RAG-2 genes and evidence for secondary rearrangements in human germinal center B lymphoeytes. Fur J Immunol.1998;28,3506-3513.
173. Lantelme E., Palermo B., Granziero L., Mantovani S., Campanelli R., Monafo V., Lanzavecchia A., Giachino C. Cutting edge: recombinase-activating gene expression and V(D)J recombination in CD4+CD3 low mature T lymphocytes. J Immunol. 2000; 164,3455-3459.
174. Tran AH., Mrkobrada M., Wu GE. Identification of potential regulatory elements in the human immunoglobulin loci. Blood Cells Mol Dis. 2002 ;29, 86-93.
175. 戴晓天, 杨和平. hnRNP A2/ B1 在肺癌组织中的表达及其临床意义. 第三军医大学学报.2005; 27(5),418-421.
176. Rosenfeld J., Capdevielle J., Guillemot JC., Ferrara P. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis.Anal Biochem. 1992 ;203,173-179.
177. Wolkersd?rfer GW., Haase M., Morgner A., Baretton G., Miehlke S. Monoclonal gammopathy of undetermined significance and Russell body formation in Helicobacter pylori gastritis. Helicobacter. 2006 ; 11,506-510.
178. Vordermark D., Said HM.,Katzer A., Kuhnt T.,H?nsgen G., Dunst J. Flentje M., Bache M. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system.BMC Cancer.2006;6,207.
179. Ewan KL.,Li X.,Cheikh SBK.,Pedneault M.,Chu CW. Human kallikrein 10 ELISA development and validation in breast cancer sera.Clin Biochem. 2007; 40, 1057-1062.
180. Scholler N.,Crawford M.,Sato A.,Drescher CW.,O'Briant KC.,Kiviat N.,Anderson GL., Urban N.Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res.2006;12,2117-2124.
181. Konishi N.,Matsumoto K.,Hiasa Y.,Kitahori Y.,Hayashi I.,Matsuda H. Tissue and serum pepsinogen I and II in gastric cancer identified using immunohistochemistry and sensitive ELISA.J Clin Pathol.1995 ;48,364-367.
182. 马大昌,武力,王育成,马宇光,张煦. CXCR4 单克隆抗体对人乳腺癌细胞 MCF -7 凋亡的影响. 现代肿瘤医学.2006;14(11),1383-1385.
183. Yoshida M, Yasuda T, Hiramitsu T, Ito H, Nakamura T. Induction of apoptosis by anti-CD44 antibody in human chondrosarcoma cell line SW1353. Biomed Res. 2008 ;29,47-52.
184. Li SL, Ma YF, Liu GC, Zhang J, Bai HL, Liu YJ.Leukemic cell apoptosis induced by anti-human DR5 monoclonal antibody mDRA-6. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007 ;23,754-756.
185. 李耕,张学庸,樊代明,胡家露. 单克隆抗体 MG7 抑制胃癌细胞粘附和运动功能的初步研究. 现代肿瘤杂志. 1994;2(1),20-21.